<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7711671</article-id><article-id pub-id-type="pmcid-ver">PMC7711671.1</article-id><article-id pub-id-type="pmcaid">7711671</article-id><article-id pub-id-type="pmcaiid">7711671</article-id><article-id pub-id-type="pmid">33096737</article-id><article-id pub-id-type="doi">10.3390/vaccines8040621</article-id><article-id pub-id-type="publisher-id">vaccines-08-00621</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7016-2468</contrib-id><name name-style="western"><surname>Chasaide</surname><given-names initials="CN">Caitl&#237;n N&#237;</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mills</surname><given-names initials="KHG">Kingston H.G.</given-names></name><xref rid="c1-vaccines-08-00621" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-08-00621">School of Biochemistry and Immunology, Trinity College Dublin, 2, D02 PN40 Dublin, Ireland; <email>nichasac@tcd.ie</email></aff><author-notes><corresp id="c1-vaccines-08-00621"><label>*</label>Correspondence: <email>kingston.mills@tcd.ie</email>; Tel.: +353-1-8963573</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2020</year></pub-date><volume>8</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">370024</issue-id><elocation-id>621</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>10</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>04</day><month>12</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-29 15:25:12.000"><day>29</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-08-00621.pdf"/><abstract><p>Immunization with current acellular pertussis (aP) vaccines protects against severe pertussis, but immunity wanes rapidly after vaccination and these vaccines do not prevent nasal colonization with <italic toggle="yes">Bordetella pertussis</italic>. Studies in mouse and baboon models have demonstrated that Th1 and Th17 responses are integral to protective immunity induced by previous infection with <italic toggle="yes">B. pertussis</italic> and immunization with whole cell pertussis (wP) vaccines. Mucosal Th17 cells, IL-17 and secretory IgA (sIgA) are particularly important in generating sustained sterilizing immunity in the nasal cavity. Current aP vaccines induce potent IgG and Th2-skewed T cell responses but are less effective at generating Th1 and Th17 responses and fail to prime respiratory tissue-resident memory T (T<sub>RM</sub>) cells, that maintain long-term immunity at mucosal sites. In contrast, a live attenuated pertussis vaccine, pertussis outer membrane vesicle (OMV) vaccines or aP vaccines formulated with novel adjuvants do induce cellular immune responses in the respiratory tract, especially when delivered by the intranasal route. An increased understanding of the mechanisms of sustained protective immunity, especially the role of respiratory T<sub>RM</sub> cells, will facilitate the development of next generation pertussis vaccines that not only protect against pertussis disease, but prevent nasal colonization and transmission of <italic toggle="yes">B. pertussis</italic>.</p></abstract><kwd-group><kwd><italic toggle="yes">Bordetella pertussis</italic></kwd><kwd>pertussis vaccine</kwd><kwd>T cells</kwd><kwd>Th1 cells</kwd><kwd>Th17 cells</kwd><kwd>memory T cells</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-08-00621"><title>1. Introduction</title><p>Pertussis, or whooping cough, is caused by the Gram-negative bacterium <italic toggle="yes">Bordetella pertussis</italic>, which infects the upper and lower respiratory tract, causing considerable morbidity in children and adults and severe disease that can be fatal in infants [<xref rid="B1-vaccines-08-00621" ref-type="bibr">1</xref>]. The clinical features of disease include a paroxysmal cough, creating a characteristic &#8216;whoop&#8217;, leukocytosis and in some cases pneumonia. Dissemination of <italic toggle="yes">B. pertussis</italic> to other organs occurs very rarely, and only occurs in immunocompromised individuals [<xref rid="B2-vaccines-08-00621" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-08-00621" ref-type="bibr">3</xref>]. Whole cell pertussis (wP) vaccines, developed in the 1940s are effective at preventing pertussis, but are associated with significant adverse events, including febrile convulsions [<xref rid="B4-vaccines-08-00621" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-08-00621" ref-type="bibr">5</xref>]. This led to their discontinuation in most high-income countries and the development of acellular pertussis (aP) vaccines, now widely used in these countries [<xref rid="B6-vaccines-08-00621" ref-type="bibr">6</xref>]. aP vaccines contain between 2 and 5 <italic toggle="yes">B. pertussis</italic> antigens, all of which include the major symptom-causing virulence factor, pertussis toxin (PT), as well as various combinations of filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae 2 and 3 (FIM2/3) [<xref rid="B7-vaccines-08-00621" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-08-00621" ref-type="bibr">8</xref>]. aP vaccines administered as part of the primary immunization of infant and young children also contain diphtheria and tetanus toxoids, termed DTaP, whereas booster vaccines, termed Tdap, have reduced antigen content [<xref rid="B9-vaccines-08-00621" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-08-00621" ref-type="bibr">10</xref>]. All current aP vaccines are formulated with alum as the adjuvant. Clinical trials carried out in the 1990s showed that the aP vaccines had excellent safety profiles and were capable of preventing severe disease [<xref rid="B11-vaccines-08-00621" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-08-00621" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-08-00621" ref-type="bibr">13</xref>]. However, recent studies in animal models have indicated that immunization with aP vaccines does not prevent nasal colonization or transmission of <italic toggle="yes">B. pertussis</italic> [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>].</p><p>Pertussis remains a global problem with the highest case rates of any vaccine-preventable disease [<xref rid="B17-vaccines-08-00621" ref-type="bibr">17</xref>]. Many pertussis-related deaths still occur in low- and middle-income countries, however, these deaths are not attributable to poor efficacy of wP vaccines but to gaps in vaccination coverage and limited access to healthcare in these countries [<xref rid="B18-vaccines-08-00621" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-08-00621" ref-type="bibr">19</xref>]. However, a resurgence in pertussis has been observed in the last decades in countries with high aP vaccine coverage, suggesting that immunization with aP vaccines does not generate sustained sterilizing immunity against <italic toggle="yes">B. pertussis</italic> [<xref rid="B20-vaccines-08-00621" ref-type="bibr">20</xref>]. Furthermore, epidemiological data have demonstrated that immunization with wP vaccines is more effective at preventing cases of pertussis than aP vaccines [<xref rid="B21-vaccines-08-00621" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-08-00621" ref-type="bibr">22</xref>]. Currently, the World Health Organization has recommended that countries still using wP vaccines should not switch to aP vaccines, but it is generally accepted that the reintroduction of wP vaccines would not be possible in countries where it is deemed unsafe.</p><p>There are a number of possible reasons for the failure of aP vaccines to generate potent and sustained immunity. In addition to the problem of pertussis in infants too young to be immunized, there are increasing numbers of cases in preadolescents, adolescents and adults, suggesting immunity wanes after immunization with aP vaccines. Indeed, rapid waning of protective immunity has been reported even after five doses of DTaP [<xref rid="B23-vaccines-08-00621" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-08-00621" ref-type="bibr">24</xref>]. Although booster vaccination may provide a solution, Tdap boosting only provides significant protection for up to 1 year, and protection substantially wanes 2&#8211;3 years later [<xref rid="B25-vaccines-08-00621" ref-type="bibr">25</xref>]. The emergence of <italic toggle="yes">B. pertussis</italic> strains with deletions or mutations in the antigens present in aP vaccines, which may be caused by vaccine-driven immune selective pressure, could also provide an explanation for the persistence of <italic toggle="yes">B. pertussis</italic> in populations immunized with aP vaccines [<xref rid="B26-vaccines-08-00621" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-08-00621" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-08-00621" ref-type="bibr">28</xref>].</p><p>Weak or inappropriate cell-mediated immune responses generated by aP vaccines may also be responsible for the resurgence of pertussis in vaccinated populations. Immunization with aP vaccines induces strong serum immunoglobulin G (IgG) and predominantly Th2-type T cell responses [<xref rid="B29-vaccines-08-00621" ref-type="bibr">29</xref>]. However, extensive studies in mouse and baboon models of <italic toggle="yes">B. pertussis</italic> infection have demonstrated that robust Th1 and Th17 cell responses are required for optimum protective immunity [<xref rid="B30-vaccines-08-00621" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-08-00621" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>]. Furthermore, recent reports have indicated that tissue-resident memory T (T<sub>RM</sub>) cells in the upper and lower respiratory tract induced by previous infection or intranasal (i.n.) immunization play a crucial role in long-term protective immunity in the nose and lungs [<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>,<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>].</p><p>While immunization with aP vaccines appears to be capable of protecting against severe pertussis disease in infants, there is increasing evidence from animal models that the immunity generated with aP vaccines does not prevent infection of nasal mucosae [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>]. Asymptomatic carriage in aP-immunized baboons can lead to the transmission of <italic toggle="yes">B. pertussis</italic> to na&#239;ve animals [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>] and mathematical modelling studies have suggested that asymptomatic carriage and transmission may also occur in the human population and may account for the recent resurgence of pertussis cases in certain countries [<xref rid="B35-vaccines-08-00621" ref-type="bibr">35</xref>]. This poses a significant risk to infants who have not yet received or completed their DTaP immunization program, and it may impede the potential to generate herd immunity in the population [<xref rid="B24-vaccines-08-00621" ref-type="bibr">24</xref>,<xref rid="B36-vaccines-08-00621" ref-type="bibr">36</xref>]. Recent studies have suggested that local immunity, especially IL-17 producing T<sub>RM</sub> responses, as well as mucosal IgA, may be central to the induction of sterilizing protective immunity in the nasal cavity [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>]. Therefore, strategies for the design of improved pertussis vaccines must consider the induction of mucosal immunity in the respiratory tract.</p><p>This review outlines the state of the art in pertussis vaccine research, discusses current licensed vaccines, vaccines in development, as well as those at an experimental stage, and focuses particularly on how immunity is achieved at a molecular and cellular level. We also discuss the mechanism of natural and vaccine-induced immunity and how effective pertussis vaccines can be designed using immunization approaches that induce cellular as well as humoral immunity, especially local T cell responses in the respiratory tract.</p></sec><sec id="sec2-vaccines-08-00621"><title>2. Immune Responses That Control a Primary Infection with <italic toggle="yes">B. pertussis</italic></title><p>Natural immunity generated by previous infection is considered to be more effective than immunity generated with aP or wP vaccines. Therefore, an understanding of the mechanism of natural immunity in the respiratory tract should assist in the design of a more effective pertussis vaccine. Following recovery from infection with <italic toggle="yes">B. pertussis</italic>, convalescent animals and humans have long-term, but not life-long, protection against subsequent infection through the generation of immunological memory [<xref rid="B37-vaccines-08-00621" ref-type="bibr">37</xref>]. Although correlates of protective immunity have not yet been fully elucidated, or unanimously agreed upon, there is a wealth of knowledge from recent research on the mechanisms of innate and adaptive immunity to <italic toggle="yes">B. pertussis</italic> that control primary infection and prevent re-infection with <italic toggle="yes">B. pertussis</italic>.</p><p>Primary infection with <italic toggle="yes">B. pertussis</italic> can broadly be described in three stages, which include the recognition, bactericidal clearance and memory stages [<xref rid="B38-vaccines-08-00621" ref-type="bibr">38</xref>]. During the recognition stage, bacteria adhere to ciliated epithelia of the upper respiratory mucosa, and <italic toggle="yes">B. pertussis</italic> is detected by resident innate immune cells, which provide a rapid first line of defense [<xref rid="B39-vaccines-08-00621" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-08-00621" ref-type="bibr">40</xref>]. These cells include airway mucosal dendritic cells (DCs), which reside between epithelial cells and survey airway mucosa for pathogens [<xref rid="B41-vaccines-08-00621" ref-type="bibr">41</xref>]. Alveolar macrophages (AMs), present on the mucosal surface of the lungs, phagocytose and kill bacteria rapidly upon their recognition. Depletion of AM using chlodronate liposomes increases <italic toggle="yes">B. pertussis</italic> burden in the respiratory tract of mice [<xref rid="B42-vaccines-08-00621" ref-type="bibr">42</xref>]. The recognition of <italic toggle="yes">B. pertussis</italic> pathogen-associated molecular patterns (PAMPs), such as pertussis toxin (PT), lipopolysaccharide (LPS) and lipopeptides, by pattern recognition receptors (PRRs) is crucial for macrophage and DC responses. Mice lacking the toll-like-receptor (TLRs) adaptor, MyD88 adaptor-like protein (Mal), have increased infection in the lungs and bacterial dissemination to the liver, with often fatal consequences [<xref rid="B43-vaccines-08-00621" ref-type="bibr">43</xref>]. These mice also show reduced lung resident AMs following <italic toggle="yes">B. pertussis</italic> infection, whereas wild-type (WT) mice had increasing numbers of AMs in the lung throughout the course of infection [<xref rid="B44-vaccines-08-00621" ref-type="bibr">44</xref>]. Airway mucosal DCs process bacterial antigens migrate to the lymph nodes, where they present peptide antigens to na&#239;ve T cells [<xref rid="B45-vaccines-08-00621" ref-type="bibr">45</xref>].</p><p>Studies in mouse models have shown that in the bactericidal stage, inflammatory macrophages and DCs infiltrate the lung from the periphery. In addition to their function as antigen presenting cells (APCs), DCs also produce pro-inflammatory cytokines and chemokines in response to PAMPs, including LPS binding to TLR4, that promote the recruitment and activation of other innate immune cells and effector T cells. DCs and macrophages also produce the anti-inflammatory cytokine IL-10, which may protect the lung from excessive inflammation and immunopathology [<xref rid="B46-vaccines-08-00621" ref-type="bibr">46</xref>]. DCs expressing the integrins CD11c, CD8&#945; and the E-cadherin receptor, CD103, infiltrate the lung early in <italic toggle="yes">B. pertussis</italic> infection and are required for effective bacterial clearance [<xref rid="B47-vaccines-08-00621" ref-type="bibr">47</xref>]. IL-17-producing &#947;&#948; T cells are detected in the mouse lung as early as 2 h post-infection [<xref rid="B48-vaccines-08-00621" ref-type="bibr">48</xref>]. Inhibition of this early innate IL-17 produced by &#947;&#948; T cells, by treatment of mice with IL-17 neutralizing antibodies 1 day prior and 2 days after infection, led to increased bacterial burden at 3 and 7 days post bacterial challenge and this was associated with reduced local production of protective antimicrobial peptides (AMPs) in the lungs [<xref rid="B48-vaccines-08-00621" ref-type="bibr">48</xref>].</p><p>IL-17 produced by &#947;&#948; T cells and Th17 cells helps to promote recruitment of neutrophils to the respiratory tract. Neutrophil numbers peak in the lung at 5-7 days post challenge in mice, and have the capacity to phagocytose and kill <italic toggle="yes">B. pertussis</italic>, but are not essential for clearance of bacteria from the lungs during primary infection [<xref rid="B49-vaccines-08-00621" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-08-00621" ref-type="bibr">50</xref>]. They do, however, play an important role in the protection of immune mice from reinfection, which is believed to be due to bacterial killing via antibody-mediated phagocytosis [<xref rid="B49-vaccines-08-00621" ref-type="bibr">49</xref>]. Furthermore, we have found that neutrophils play a central role in clearance of primary and secondary infections of the nasal mucosae with <italic toggle="yes">B. pertussis</italic> (Borkner, Curham and Mills, unpublished data).</p><p>NK cells, which infiltrate the lungs of mice around day 7-14 of infection, are an important early source of IFN-&#947; that activates the bactericidal activity of macrophages [<xref rid="B51-vaccines-08-00621" ref-type="bibr">51</xref>] and promotes phagolysosomal maturation [<xref rid="B52-vaccines-08-00621" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-08-00621" ref-type="bibr">53</xref>]. Macrophages and epithelial cells can act as a niche for intracellular survival of <italic toggle="yes">B. pertussis</italic> and IFN-&#947; appears to play a key role in eliminating this intracellular reservoir of live bacteria [<xref rid="B54-vaccines-08-00621" ref-type="bibr">54</xref>]. IFN-&#947; produced by NK cells also promotes polarization of Th1 cells, and depletion of NK cells causes a shift from Th1 to Th2 responses and leads to bacterial dissemination to the liver [<xref rid="B51-vaccines-08-00621" ref-type="bibr">51</xref>].</p><p>While innate immune responses can effectively limit bacterial growth in the respiratory tract, they do not clear the infection with <italic toggle="yes">B. pertussis</italic>. The adaptive arm of the immune system is required for bactericidal clearance of <italic toggle="yes">B. pertussis</italic>. CD4 T helper (Th) cells are activated by <italic toggle="yes">B. pertussis</italic> antigens presented by APCs in lymph nodes draining the respiratory tract. These CD4 T cells undergo clonal expansion and are indispensable for clearance of <italic toggle="yes">B. pertussis</italic> from the lungs and probably the nasal cavity [<xref rid="B52-vaccines-08-00621" ref-type="bibr">52</xref>,<xref rid="B55-vaccines-08-00621" ref-type="bibr">55</xref>]. There is strong evidence that Th1 cells are responsible for the effective clearance of <italic toggle="yes">B. pertussis</italic> from the lungs and there is emerging evidence that Th17 cells mediate clearance from the nasal cavity [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>,<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>]. CD4 T follicular helper (Tfh) cells play an important role in the formation of germinal centers (GCs) and the induction of antibody production and affinity maturation by B cells [<xref rid="B57-vaccines-08-00621" ref-type="bibr">57</xref>]. Tfh cells are induced by <italic toggle="yes">B. pertussis</italic> infection and may also play a role in generating of <italic toggle="yes">B. pertussis</italic>-specific antibodies (Wilk, Allen and Mills, unpublished data).</p><p>Finally, in the <bold>memory</bold> stage, following clearance of <italic toggle="yes">B. pertussis</italic> from the respiratory tract, the number of effector T and B cells contracts, but populations of memory B and T cells are generated and persist to maintain long-lived immunity against re-infection [<xref rid="B37-vaccines-08-00621" ref-type="bibr">37</xref>,<xref rid="B55-vaccines-08-00621" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>].</p></sec><sec id="sec3-vaccines-08-00621"><title>3. Natural and Vaccine-Induced Immunity-Correlates of Protection</title><sec id="sec3dot1-vaccines-08-00621"><title>3.1. Antibody Responses</title><sec id="sec3dot1dot1-vaccines-08-00621"><title>3.1.1. Serum IgG</title><p>Current aP vaccines generate high levels of antibody and associated Th2 responses (<xref ref-type="fig" rid="vaccines-08-00621-f001">Figure 1</xref>), and this is consistent with many alum-adjuvanted vaccines [<xref rid="B58-vaccines-08-00621" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-08-00621" ref-type="bibr">59</xref>]. Clinical trials in 1990s demonstrated that immunization of children with aP vaccines induced potent serum IgG responses specific for the vaccine antigens and prevented severe pertussis [<xref rid="B13-vaccines-08-00621" ref-type="bibr">13</xref>,<xref rid="B60-vaccines-08-00621" ref-type="bibr">60</xref>]. However, recent evidence suggests that aP-induced immunity does not confer protection against bacterial carriage, which is reflected in an increase in the incidence of pertussis in countries with high vaccine coverage [<xref rid="B61-vaccines-08-00621" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-08-00621" ref-type="bibr">62</xref>]. The nature of the antibody isotypes generated, the limited breadth of their antigenic specificity as well as rapid waning of serum antibody concentrations may contribute to this suboptimal protection [<xref rid="B23-vaccines-08-00621" ref-type="bibr">23</xref>,<xref rid="B63-vaccines-08-00621" ref-type="bibr">63</xref>].</p><p>During natural infection with <italic toggle="yes">B. pertussis</italic>, antigen-specific IgG is only detectable in the serum late in infection when the bacteria are almost cleared from the lung, suggesting that circulating antibodies do not play a major role clearing a primary infection with <italic toggle="yes">B. pertussis</italic>, but may play a role in preventing re-infection [<xref rid="B55-vaccines-08-00621" ref-type="bibr">55</xref>]. Infection with <italic toggle="yes">B. pertussis</italic> or immunization with wP vaccines induce IgG2a/IgG2c in mice and a corresponding IgG1 response in humans. However, the strong serum antibody response generated by aP vaccines is predominantly of the IgG1 subclass in mice, or, its functional equivalent, IgG4 in humans [<xref rid="B64-vaccines-08-00621" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-08-00621" ref-type="bibr">65</xref>]. IgG subclasses are determined by class switching of mature B cells, which occurs through cell&#8211;cell interaction between B and T cells, as well as by cytokines secreted by T cells [<xref rid="B66-vaccines-08-00621" ref-type="bibr">66</xref>]. IgG2a/IgG2c-skewed B cell class switching is associated with Th1-derived IFN-&#947; [<xref rid="B67-vaccines-08-00621" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-08-00621" ref-type="bibr">68</xref>], whereas IgG1 antibodies are associated with Th2 interactions and associated cytokine signaling [<xref rid="B69-vaccines-08-00621" ref-type="bibr">69</xref>].</p><p>In addition to overall levels and specificity, antibody function is an important determinant of effective bacterial clearance, especially opsonizing antibodies which bind <italic toggle="yes">B. pertussis</italic> and promote bacterial uptake and killing by macrophages and neutrophils [<xref rid="B54-vaccines-08-00621" ref-type="bibr">54</xref>,<xref rid="B70-vaccines-08-00621" ref-type="bibr">70</xref>]. Phagocytosis can also occur by binding of the complement receptor 3 (CR3), but this mechanism of entry is hijacked by <italic toggle="yes">B. pertussis</italic> to promote intracellular survival [<xref rid="B70-vaccines-08-00621" ref-type="bibr">70</xref>]. In contrast, uptake via the IgG Fc receptor, Fc&#947;RIII, leads to increased <italic toggle="yes">B. pertussis</italic> clearance when compared to CR3-mediated phagocytosis [<xref rid="B70-vaccines-08-00621" ref-type="bibr">70</xref>]. The IgG subclass can influence opsonization and downstream phagocyte effector function [<xref rid="B71-vaccines-08-00621" ref-type="bibr">71</xref>]. IgG1 and IgG3, present in serum from subjects vaccinated with the live attenuated pertussis vaccine BPZE1, effectively opsonized <italic toggle="yes">B. pertussis</italic>, whereas IgG2 and IgG4 were the dominant subclass, but opsonizing antibodies were low or absent in the serum from individuals immunized with an aP vaccine [<xref rid="B72-vaccines-08-00621" ref-type="bibr">72</xref>]. Taken together, these studies show that the ratio of different IgG subclasses generated following vaccination may influence the outcome of infection, as a result of functional differences in the antibodies and their associated T cell responses.</p></sec><sec id="sec3dot1dot2-vaccines-08-00621"><title>3.1.2. Secretory IgA</title><p>During primary infection of mice and humans with <italic toggle="yes">B. pertussis</italic>, secretory IgA (sIgA) is detected in nasopharyngeal secretions, before the detection of IgG [<xref rid="B55-vaccines-08-00621" ref-type="bibr">55</xref>,<xref rid="B73-vaccines-08-00621" ref-type="bibr">73</xref>]. IgA can provide early defense against bacterial adherence to epithelial cells [<xref rid="B73-vaccines-08-00621" ref-type="bibr">73</xref>], can opsonize <italic toggle="yes">B. pertussis</italic> and enhance binding, uptake and killing of bacteria in human polymorphonuclear cells, the latter being mediated by the myeloid-expressed IgA receptor, Fc&#945;RI [<xref rid="B74-vaccines-08-00621" ref-type="bibr">74</xref>]. IL-17 production by Th17 cells has been shown to be important for the generation of sIgA. The induction of Th17 cells by parenteral priming followed by an intranasal (i.n.) boosting with a Group A streptococcal C5a peptidase (ScpA) vaccine correlated with increased local sIgA-producing B cells [<xref rid="B75-vaccines-08-00621" ref-type="bibr">75</xref>]. This IgA-inducing function may be mediated by Th17-driven expression of the poly-Ig receptor (pIgR), which is involved in sIgA secretion from airway lumen epithelial cells [<xref rid="B75-vaccines-08-00621" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-08-00621" ref-type="bibr">76</xref>]. A study using the live-attenuated <italic toggle="yes">B. pertussis</italic> vaccine, BPZE1, demonstrated that IL-17-dependent sIgA is not only important in the primary response to <italic toggle="yes">B. pertussis</italic>, but also in vaccine-induced immunity [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>]. Transfer of nasal washes from BPZE1-immunized mice conferred protection against <italic toggle="yes">B. pertussis</italic> infection; however, this protection could not be conferred by transfer of nasal washes from IgA or pIgR deficient mice [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>].</p></sec></sec><sec id="sec3dot2-vaccines-08-00621"><title>3.2. CD4 Th Cell Subtypes</title><sec id="sec3dot2dot1-vaccines-08-00621"><title>3.2.1. Th1 Cells Protect in the Lung</title><p>The importance of T cell responses in generating long-lived immunity to many pathogens, including <italic toggle="yes">B. pertussis</italic>, is becoming increasingly evident, and natural infection with <italic toggle="yes">B. pertussis</italic> generates strong Th1 and Th17 responses which mediate effective protection against respiratory infection in animal models [<xref rid="B30-vaccines-08-00621" ref-type="bibr">30</xref>,<xref rid="B55-vaccines-08-00621" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>]. A similar, albeit weaker Th1/Th17-skewed response and associated protection is generated by immunization with wP vaccines [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>]. Conversely, aP vaccines induce strongly Th2-skewed responses, which are associated with the production of the cytokines IL-4, IL-5 and IL-13 [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>]. Th1 responses have a well-established role in protective immunity in the lungs induced by natural infection with <italic toggle="yes">B. pertussis</italic> in animal models [<xref rid="B30-vaccines-08-00621" ref-type="bibr">30</xref>,<xref rid="B55-vaccines-08-00621" ref-type="bibr">55</xref>]. Th1 cells characteristically produce the pleiotropic inflammatory cytokine, IFN-&#947;, and its signaling is crucial for protection against lung infection with <italic toggle="yes">B. pertussis</italic> in mice [<xref rid="B30-vaccines-08-00621" ref-type="bibr">30</xref>,<xref rid="B52-vaccines-08-00621" ref-type="bibr">52</xref>]. Ablation of IFN-&#947; signaling, using IFN-&#947; receptor knockout mice (IFN-&#947;R<sup>-/-</sup>), leads to severe disseminating infection and in some cases fatal disease [<xref rid="B30-vaccines-08-00621" ref-type="bibr">30</xref>]. Th1 cells also play an essential role in protection conferred with wP vaccines; IFN-&#947;R<sup>-/-</sup> mice immunized with wP vaccines have 100-1000 fold higher <italic toggle="yes">B. pertussis</italic> load in the lung at days 3, 7 and 10 post challenge, when compared with WT mice immunized with the same vaccine [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>,<xref rid="B77-vaccines-08-00621" ref-type="bibr">77</xref>].</p><p>Further evidence supporting the crucial role of Th1 cells in host immunity against <italic toggle="yes">B. pertussis</italic> is provided by the immune evasion mechanisms employed by <italic toggle="yes">B. pertussis</italic> to evade the protective role of IFN-&#947; [<xref rid="B78-vaccines-08-00621" ref-type="bibr">78</xref>]. IL-10 is an anti-inflammatory cytokine, which can be produced by regulatory T (Treg) cells as well as macrophages and DCs, and myeloid cell-derived IL-10 can promote the induction of Treg cells [<xref rid="B79-vaccines-08-00621" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-08-00621" ref-type="bibr">80</xref>]. IL-10-producing Tr1-type Treg cells are induced in the lung during <italic toggle="yes">B. pertussis</italic> infection driven by innate IL-10 induced by FHA [<xref rid="B81-vaccines-08-00621" ref-type="bibr">81</xref>] and possibly other <italic toggle="yes">B. pertussis</italic> virulence factors. These <italic toggle="yes">B. pertussis</italic>-specific Tr1 cells suppress protective Th1 cells, highlighting the selective advantage gained by <italic toggle="yes">B. pertussis</italic> in subverting host immunity through skewing the T cell response towards a more Treg phenotype [<xref rid="B81-vaccines-08-00621" ref-type="bibr">81</xref>]. Although the weight of evidence suggests that CD4 Th cells are the major protective T cells in <italic toggle="yes">B. pertussis</italic> infection, CD8 cytotoxic T cells (CTLs), which also produce IFN-&#947;, may also play a role, especially against intracellular bacteria [<xref rid="B82-vaccines-08-00621" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-08-00621" ref-type="bibr">83</xref>].</p><p>There is a bias toward Th2 differentiation in neonates [<xref rid="B58-vaccines-08-00621" ref-type="bibr">58</xref>,<xref rid="B84-vaccines-08-00621" ref-type="bibr">84</xref>]. This may reflect high expression of IL-4 and the Th2 transcription factor, GATA3 and hypomethylation of the Th2 locus, which includes <italic toggle="yes">il4</italic>, <italic toggle="yes">il13</italic> and <italic toggle="yes">il5</italic> genes [<xref rid="B85-vaccines-08-00621" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-08-00621" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-08-00621" ref-type="bibr">87</xref>]. Nevertheless, there is evidence that both natural infection and immunization with wP vaccines in infants as young as 2&#8211;6 months can generate Th1 responses [<xref rid="B29-vaccines-08-00621" ref-type="bibr">29</xref>,<xref rid="B88-vaccines-08-00621" ref-type="bibr">88</xref>]. These studies show that the predilection for Th2 immunity in neonates can be overcome through immunization with wP vaccines, suggesting that these vaccines may include appropriate components that stimulate innate immune responses that direct the induction of Th1 cells. This is an important consideration for the design of novel aP vaccines for administration to neonates.</p></sec><sec id="sec3dot2dot2-vaccines-08-00621"><title>3.2.2. Th17 Cells Protect Against Nasal Colonization</title><p>Th17 cells have more recently been identified as key players in protecting mucosal surfaces against infection with candida and extracellular bacteria [<xref rid="B89-vaccines-08-00621" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-08-00621" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-08-00621" ref-type="bibr">91</xref>]. Many early studies on <italic toggle="yes">B. pertussis</italic> focused primarily on the mechanism of immunity in the lung, but recent studies from mouse and baboon models have shown that IL-17 and Th17 cells in the nasal mucosae may play pivotal roles in natural and vaccine-induced immunity in the nasopharynx [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>,<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>,<xref rid="B92-vaccines-08-00621" ref-type="bibr">92</xref>].</p><p>Th17 cells are polarized by the inflammatory cytokines IL-1&#946;, IL-23 and IL-6. Early evidence for the role of Th17 cells in protection against <italic toggle="yes">B. pertussis</italic> came from studies that showed that immunization with a wP vaccine generated a population of IL-17-producing CD4 T cells [<xref rid="B93-vaccines-08-00621" ref-type="bibr">93</xref>]. These Th17 cells played a role in wP vaccine-induced protection against lung infection and their induction was dependent on innate TLR4 signaling and the production of IL-23 and IL-1, highlighting the importance of vaccine-induced innate immune activation in promoting effective adaptive immune responses [<xref rid="B93-vaccines-08-00621" ref-type="bibr">93</xref>]. The generation of <italic toggle="yes">B. pertussis</italic>-specific Th17 cells is dependent on NLRP3 inflammasome-driven IL-1&#946; production in macrophages or DCs and this is activated by the pore-forming capacity of the <italic toggle="yes">B. pertussis</italic> virulence factor, adenylate cyclase toxin (ACT) [<xref rid="B94-vaccines-08-00621" ref-type="bibr">94</xref>].</p><p>Th17 cells are necessary for the effective clearance of <italic toggle="yes">B. pertussis</italic> from the lungs by promoting recruitment of neutrophils and inflammatory macrophages to the respiratory tract [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>,<xref rid="B93-vaccines-08-00621" ref-type="bibr">93</xref>]. Mice defective in IL-17 have impaired clearance of <italic toggle="yes">B. pertussis</italic> from the lung, which is associated with reduced neutrophil recruitment following <italic toggle="yes">B. pertussis</italic> challenge [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>,<xref rid="B94-vaccines-08-00621" ref-type="bibr">94</xref>]. Adoptive transfer of Th1 or Th17 cells from convalescent to na&#239;ve mice enhanced clearance of <italic toggle="yes">B. pertussis</italic> from the lung, but the greatest protection was observed when a combination of Th1 and Th17 cells were transferred, indicating a protective role in the lungs for both cell types [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>].</p><p>While Th1 and Th17 cells contribute to protective immunity generated by immunization with wP vaccines, studies in IL-4<sup>-/-</sup> mice demonstrated that the strong Th2-skewed cellular responses generated following immunization with aP vaccines were dispensable for the protection in the lungs [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>]. However, aP-induced protection in the lungs was significantly impaired in IL-17-defective mice providing further evidence of a role for Th17 in pertussis vaccine-induced immunity [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>].</p><p>In the baboon model, sterilizing immunity is generated by previous infection with <italic toggle="yes">B. pertussis</italic> and this is associated with production of mucosal IL-17 and the generation of long-lived memory Th17 cells [<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>]. High concentrations of IL-17 were found in nasal washes on days 5 and 7 of <italic toggle="yes">B. pertussis</italic> infection and this was accompanied by high levels of Th17-polarising cytokines IL-1&#946;, IL-23, IL-6 [<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>]. Long-lived CD95<sup>+</sup> CD4<sup>+</sup> memory T cells that secreted IL-17 or IFN-&#947; were detected in baboons up to two years following challenge with <italic toggle="yes">B. pertussis</italic> [<xref rid="B56-vaccines-08-00621" ref-type="bibr">56</xref>]. Furthermore, immunization with wP vaccines protected against nasopharyngeal colonization and disease [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>]. However, while natural infection or immunization with a wP vaccine generated Th1/Th17 responses, aP vaccines generated predominantly Th2 responses [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>]. Furthermore, immunization of baboons with an aP vaccine protected against clinical disease, but was ineffective at protecting against nasal colonization with <italic toggle="yes">B. pertussis</italic> or transmission of bacteria to naive baboons [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>]. While natural infection or immunization with either vaccine generates strong IgG responses against PT, FHA, PRN and FIM, the inability of aP vaccines to prevent nasal infection may be attributed to their limited ability to induce an effective cellular immune response, especially memory Th17 cells in the respiratory tract. </p><p>In humans, vaccination with wP vaccines has also been shown to generate Th17 as well as Th1 responses [<xref rid="B95-vaccines-08-00621" ref-type="bibr">95</xref>]. The nature of the initial priming dose of the vaccine dictates long term polarization of memory T cells [<xref rid="B59-vaccines-08-00621" ref-type="bibr">59</xref>,<xref rid="B95-vaccines-08-00621" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-08-00621" ref-type="bibr">96</xref>]. A recent study reported that boosting with Tdap more than 15 years after the primary vaccination with five doses of DTwP generated greater PT-specific CD4 T cell responses, enhanced proliferative capacity of memory T cells and induced higher numbers of Th17 and Th1 cells than in individuals primed with DTaP vaccines [<xref rid="B95-vaccines-08-00621" ref-type="bibr">95</xref>]. Transcriptomic analysis showed upregulation of IL-17 and IFN-&#947; gene expression in the DTwP-primed individuals, and upregulation of IL-4 and IL-9 in the DTaP-primed individuals [<xref rid="B95-vaccines-08-00621" ref-type="bibr">95</xref>]. A study in children primed with aP or wP vaccines and boosted with an aP vaccine at 9 years of age revealed lower <italic toggle="yes">B. pertussis</italic>-specific cellular immune responses and reduced Th1/Th2 ratio in the aP-primed individuals [<xref rid="B96-vaccines-08-00621" ref-type="bibr">96</xref>]. Together, these studies indicate that the priming vaccine is of utmost importance in determining enduring T cell differentiation and memory responses.</p></sec></sec><sec id="sec3dot3-vaccines-08-00621"><title>3.3. T<sub>RM</sub> Cells Maintain Sustained Protective Immunity in the Respiratory Tract</title><p>Circulating memory T cells have classically been subdivided into effector memory (T<sub>EM</sub>) and central memory (T<sub>CM</sub>) cells based on both their homing and effector function [<xref rid="B97-vaccines-08-00621" ref-type="bibr">97</xref>]. More recently, a distinct subset of memory T cells, tissue-resident memory T (T<sub>RM</sub>) cells have been identified, which remain in tissues following infection, with little or no recirculation [<xref rid="B98-vaccines-08-00621" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-08-00621" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-08-00621" ref-type="bibr">100</xref>]. CD4 and CD8 T<sub>RM</sub> cells in humans and mice express the transmembrane C-type lectin, CD69, which plays a role in their retention within peripheral tissues [<xref rid="B101-vaccines-08-00621" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-08-00621" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-08-00621" ref-type="bibr">103</xref>]. CD8 and some CD4 T<sub>RM</sub> cells also express the &#945;<sub>E</sub> integrin CD103. CD4 T<sub>RM</sub> cells that co-express CD103 and CD69 are found in the lungs of mice following <italic toggle="yes">B. pertussis</italic> infection [<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>].</p><p>T<sub>RM</sub> cells maintain immunological memory at mucosal surfaces and are poised to act rapidly as first responders at mucosal sites [<xref rid="B104-vaccines-08-00621" ref-type="bibr">104</xref>], recruiting innate and adaptive immune cells to the site of infection [<xref rid="B105-vaccines-08-00621" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-08-00621" ref-type="bibr">106</xref>]. T<sub>RM</sub> cells possess innate-like properties and can be activated by cytokines, in the absence of TCR ligation with a cognate antigen [<xref rid="B107-vaccines-08-00621" ref-type="bibr">107</xref>]. CD8 T<sub>RM</sub> cells are particularly important in viral infections and have been studied in the greatest detail [<xref rid="B99-vaccines-08-00621" ref-type="bibr">99</xref>,<xref rid="B108-vaccines-08-00621" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-08-00621" ref-type="bibr">109</xref>]. However, CD4 T<sub>RM</sub> cells also play a role in protection against viral infections at mucosal sites [<xref rid="B103-vaccines-08-00621" ref-type="bibr">103</xref>,<xref rid="B110-vaccines-08-00621" ref-type="bibr">110</xref>]. CD4 T<sub>RM</sub> cells are retained in the lungs of mice following influenza challenge and traffic back to the lungs of na&#239;ve mice following adoptive transfer [<xref rid="B103-vaccines-08-00621" ref-type="bibr">103</xref>].</p><p>There is growing evidence that local memory T cells in the respiratory tract may mediate protective immunity against certain pathogens independent of antibody responses. Natural infection to respiratory syncytial virus (RSV) generates both lung and airway CD8 T<sub>RM</sub> cells, which protect in the absence of antibodies [<xref rid="B111-vaccines-08-00621" ref-type="bibr">111</xref>]. CD4 T<sub>RM</sub> cells induced in the airways following intranasal immunization with Venezuelan equine encephalitis replicon particles expressing the SARS-CoV nucleocapsid protein produced IFN-&#947; that mobilized CD8 T cells and protected against SARS-CoV challenge in mice [<xref rid="B112-vaccines-08-00621" ref-type="bibr">112</xref>]. Respiratory CD4 and CD8 T<sub>RM</sub>, which are induced by the infection of mice with influenza virus or through i.n. immunization with a live-attenuated virus, mediate protection against challenge with heterosubtypic influenza strains in mice [<xref rid="B113-vaccines-08-00621" ref-type="bibr">113</xref>,<xref rid="B114-vaccines-08-00621" ref-type="bibr">114</xref>]. These T<sub>RM</sub> cells have been shown to confer protection independently of antibody responses [<xref rid="B113-vaccines-08-00621" ref-type="bibr">113</xref>,<xref rid="B115-vaccines-08-00621" ref-type="bibr">115</xref>]. IL-17-producing CD4 T<sub>RM</sub> cells expanded in the lungs following <italic toggle="yes">Streptococcus pneumoniae</italic> infection were capable of preventing reinfection with a heterotypic pneumococcus [<xref rid="B116-vaccines-08-00621" ref-type="bibr">116</xref>]. Interestingly, virus-specific, lung CD8 T<sub>RM</sub> cells have been shown to be protective against bacterial pneumonia challenge through bystander activation [<xref rid="B117-vaccines-08-00621" ref-type="bibr">117</xref>]. Lung resident CD4 T<sub>RM</sub>, cells induced by various tuberculosis (TB) vaccines mediate protection against <italic toggle="yes">M. tuberculosis</italic> challenge in animal models [<xref rid="B118-vaccines-08-00621" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-08-00621" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-08-00621" ref-type="bibr">120</xref>].</p><p>The recent understanding that <italic toggle="yes">B. pertussis</italic> can asymptomatically colonize the nasal cavity has focused attention on the role of local immunity in the respiratory tract. CD4 T<sub>RM</sub> cells are expanded in the lung and nasal tissue during infection of mice with <italic toggle="yes">B. pertussis</italic> [<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>,<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>]. Blocking accumulation of T<sub>RM</sub> cells in the lungs during primary infection with <italic toggle="yes">B. pertussis</italic>, using the sphingosine-1-phosphate (S1P) receptor agonist, FTY720, which blocks T cell egress from lymph nodes, enhanced the bacterial burden in the lungs [<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>]. However, when mice were treated with FTY720 prior to and during secondary infection, the bacterial burden was similar to untreated convalescent mice, indicating that T<sub>RM</sub> cells are retained in the lung tissue after the clearance of <italic toggle="yes">B. pertussis</italic>, and proliferate locally in response to re-infection. These protective CD4 T<sub>RM</sub> cells secreted IL-17 or both IL-17 and IFN-&#947;, and expressed CD69, with or without CD103 [<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>].</p><p>IL-17 and IFN-&#947; secreting CD4 T<sub>RM</sub> cells accumulate in the lung parenchyma and nasal tissue soon after <italic toggle="yes">B. pertussis</italic> challenge of mice immunized with a wP vaccine [<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>]. Mice immunized with a wP vaccine rapidly cleared bacteria from the lungs following <italic toggle="yes">B. pertussis</italic> challenge. In contrast, bacterial clearance from the lungs was delayed in mice immunized with an aP vaccine. However, a striking difference was observed in the nasal cavity. Mice immunized with aP vaccines had similar or greater bacterial burden in the nasal mucosae than na&#239;ve mice following challenge with <italic toggle="yes">B. pertussis</italic>. In contrast, mice immunized with a wP vaccine had significantly reduced bacterial counts by day 3 post challenge and cleared the infection completely by day 14. CD4 T<sub>RM</sub> cells transferred from the lungs of convalescent to na&#239;ve mice one day before <italic toggle="yes">B. pertussis</italic> challenge migrated to the lungs and conferred significant protection against challenge. Conversely, transfer of splenic memory T cell from previously infected, aP or wP-immunized mice did not lead to an accumulation of T<sub>RM</sub> cells in the lung<sub>,</sub> or confer any protection in recipient mice [<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>].</p><p><italic toggle="yes">B. pertussis</italic>-specific CD69<sup>+</sup> CD4 T<sub>RM</sub> cells were found to persist in the mouse lungs for at least 7 months after <italic toggle="yes">B. pertussis</italic> challenge. Sustained protective immunity in the nasal cavity, generated by natural infection or immunization with a wP vaccine, was strongly correlated with IFN-&#947;-producing and, to an even greater extent, IL-17-producing CD69<sup>+</sup> CD4 T<sub>RM</sub> cells [<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>]. Therefore, there is growing evidence to suggest that the induction of respiratory T<sub>RM</sub> cells may be central to the generation of sterilizing immunity and long-term protection against <italic toggle="yes">B. pertussis</italic> infection of the lung and nasal mucosae.</p></sec></sec><sec id="sec4-vaccines-08-00621"><title>4. Experimental Vaccines</title><p>It is now evident from studies in mice and baboons that immunization with aP vaccines is ineffective at generating protective immunity against nasal colonization with <italic toggle="yes">B. pertussis</italic> [<xref rid="B17-vaccines-08-00621" ref-type="bibr">17</xref>] (<xref ref-type="fig" rid="vaccines-08-00621-f001">Figure 1</xref>). Although wP vaccines do confer some protection against nasal colonization, they are not as effective as previous infection with <italic toggle="yes">B. pertussis</italic> [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>] and are associated with significant side effects. Therefore, new pertussis vaccines are in development based on live attenuated <italic toggle="yes">B. pertussis</italic>, pertussis outer membrane vesicles (OMVs) or aP vaccines formulated with novel adjuvants.</p><sec id="sec4dot1-vaccines-08-00621"><title>4.1. Live Attenuated Pertussis Vaccine-BPZE1</title><p>Locht and colleagues developed a live attenuated <italic toggle="yes">B. pertussis</italic> from the Tohama-1 strain, termed BPZE1, in which three virulence factors, PT, dermonecrotic factor (DNT) and tracheal cytotoxin (TCT) are genetically modified or removed [<xref rid="B121-vaccines-08-00621" ref-type="bibr">121</xref>]. Studies in mice showed that a single i.n. immunization with BPZE1 effectively colonized the respiratory tract without generating pathology in the lung and conferred superior protection against infection with virulent <italic toggle="yes">B. pertussis</italic> compared with two doses of an aP vaccine [<xref rid="B121-vaccines-08-00621" ref-type="bibr">121</xref>]. BPZE1 has also been shown to be safe in humans in phase 1 clinical trials [<xref rid="B122-vaccines-08-00621" ref-type="bibr">122</xref>]. Furthermore, studies in baboons showed that a single i.n. dose of BPZE1 protected against nasopharyngeal colonization and pertussis disease [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B92-vaccines-08-00621" ref-type="bibr">92</xref>].</p><p>BPZE1 also generates long-lived protective immunity to <italic toggle="yes">B. pertussis</italic> in mice and this has been attributed to antibody and Th1/Th17 responses [<xref rid="B123-vaccines-08-00621" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-08-00621" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-08-00621" ref-type="bibr">125</xref>]. Transfer of serum antibodies or splenic CD4 T cells from BPZE1-immunized mice provided protection against infection in the lung with virulent <italic toggle="yes">B. pertussis</italic>, but did not protect in the nasal cavity [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>,<xref rid="B124-vaccines-08-00621" ref-type="bibr">124</xref>]. However, transfer of nasal washes from BPZE1-immunized mice to na&#239;ve mice did protect against nasal colonization [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>]. BPZE1-induced protection against nasopharyngeal colonization was dependent on the production of local sIgA and IL-17. BPZE1 immunization also generated nasal CD4 T<sub>RM</sub> cells, which produced IL-17 and, to a lesser extent, IFN-&#947;, and protection was greatly diminished in IL-17<sup>-/-</sup> mice [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>]. This study also showed that long-term protection was maintained in the nasal cavity for up to 10 months post immunization. However, nasal washes transferred at the later time point did not protect na&#239;ve mice, suggesting that sustained protective immunity generated by BPZE1 in the nasal cavity may be due to local IL-17-producing T<sub>RM</sub> cells [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>].</p><p>It was also reported that BPZE1 could induce rapid protection against <italic toggle="yes">B. pertussis</italic> infection in mice soon after immunization [<xref rid="B126-vaccines-08-00621" ref-type="bibr">126</xref>]. Mice were significantly protected at 1 week after immunization and this was dependent on TLR4 and the TLR adaptor protein, MyD88, and was completely independent of adaptive immune responses [<xref rid="B126-vaccines-08-00621" ref-type="bibr">126</xref>]. These findings suggest that BPZE1 is effective at stimulating protective innate immune responses. The studies in mouse models were translated to humans through the demonstration that human monocyte-derived DCs, cultured in vitro with BPZE1, mature similarly to those cultured with virulent <italic toggle="yes">B. pertussis</italic> and, when co-cultured with na&#239;ve T cells, these DCs promoted Th1 and Th17 differentiation [<xref rid="B127-vaccines-08-00621" ref-type="bibr">127</xref>]. A vaccine study in humans showed that immunization with BPZE1 induced strong Th1 responses, with IgG1/IgG3 serum antibodies, whereas volunteers immunized with an aP vaccine had Th2-biased responses [<xref rid="B72-vaccines-08-00621" ref-type="bibr">72</xref>]. Serum antibodies from the BPZE1-immunized individuals promoted neutrophil reactive oxygen species (ROS) production and had bactericidal killing capacity [<xref rid="B72-vaccines-08-00621" ref-type="bibr">72</xref>]. Systemic Th17 responses were not detected in this study, however mucosal T cell responses were not assessed, thus, it remains to be seen whether local airway Th17 cells are generated by immunization with BPZE1 in humans [<xref rid="B72-vaccines-08-00621" ref-type="bibr">72</xref>]. BPZE1 is currently being tested in Phase 2 clinical trials as a single i.n. immunization (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03541499">NCT03541499</ext-link>) or comparison with aP vaccine in various prime-boost vaccination strategies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03942406">NCT03942406</ext-link>).</p></sec><sec id="sec4dot2-vaccines-08-00621"><title>4.2. OMV Vaccines</title><p>OMVs are spherical structures derived from the cellular envelope of Gram-negative bacteria, which bud from actively growing cells and are composed of their outer membrane containing periplasmic components [<xref rid="B128-vaccines-08-00621" ref-type="bibr">128</xref>]. An advantage of pertussis OMV over aP vaccines is that they contain a wider variety of bacterial antigens in their natural conformation, which can elicit a broader immune response, without the same risk of over-exuberant inflammatory responses observed with wP vaccines [<xref rid="B129-vaccines-08-00621" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-08-00621" ref-type="bibr">130</xref>]. Studies in mice suggest that pertussis OMV vaccines delivered parenterally generate mixed Th1/Th2/Th17 responses as well as CD4 T<sub>RM</sub> cells, conferring protection greater than that induced with aP vaccines, and similar to that induced with wP vaccines, whilst displaying a better safety profile [<xref rid="B129-vaccines-08-00621" ref-type="bibr">129</xref>,<xref rid="B131-vaccines-08-00621" ref-type="bibr">131</xref>,<xref rid="B132-vaccines-08-00621" ref-type="bibr">132</xref>]. Zurita et al. showed that immunization of mice with a pertussis OMV vaccine conferred greater protection than an aP vaccine against a PRN(&#8722;) strain of <italic toggle="yes">B. pertussis</italic>. Immunization with the pertussis OMV vaccine also induced <italic toggle="yes">B. pertussis</italic>-specific splenic Th1 and Th17 memory responses, as well as IL-17- and IFN-&#947;-producing CD4 T<sub>RM</sub> cells in the lungs [<xref rid="B131-vaccines-08-00621" ref-type="bibr">131</xref>]. Long-term protection conferred by OMV vaccines may be mediated by cytokine-secreting T<sub>RM</sub> cells in the lung [<xref rid="B131-vaccines-08-00621" ref-type="bibr">131</xref>,<xref rid="B133-vaccines-08-00621" ref-type="bibr">133</xref>].</p><p>An OMV vaccine produced from the <italic toggle="yes">B. pertussis</italic> Tohama-1 strain, which expresses the <italic toggle="yes">B. bronchoseptica</italic> gene <italic toggle="yes">pagL</italic> encoding lipid A 3-deacylase PagL (OMV<sub>BpPagL</sub>), enhanced protection in the lungs induced with a Tdap vaccine, and provided long-term protection against multiple <italic toggle="yes">B. pertussis</italic> strains at 9 months post-immunization [<xref rid="B133-vaccines-08-00621" ref-type="bibr">133</xref>]. Studies in mice suggested that the OMV<sub>BpPagL</sub> vaccine was safer than WT OMVs; mice immunized i.n. with OMV<sub>BpPagL</sub> had less weight loss and reduced IL-6 and IL-1 production compared with mice immunized with WT OMVs [<xref rid="B134-vaccines-08-00621" ref-type="bibr">134</xref>]. OMVs generated from the <italic toggle="yes">B. pertussis</italic> B1917 strain provided comparable protection to a wP vaccine in mice, but induced lower serum IL-1&#946; and IL-6 concentrations. Induction of IL-1&#946; in particular has been associated with wP-induced neurological effects [<xref rid="B135-vaccines-08-00621" ref-type="bibr">135</xref>].</p><p>Immunization with pertussis OMV vaccine generates antibody responses with a higher IgG2a/IgG1 ratio and stronger opsonizing activity when compared with antibodies induced with aP vaccines [<xref rid="B132-vaccines-08-00621" ref-type="bibr">132</xref>]. The breadth of the antibody responses is also greater after immunization with pertussis OMV vaccines, with antibodies specific for both aP and non-aP antigens, such as GroEL, Vag8 and BrkA [<xref rid="B44-vaccines-08-00621" ref-type="bibr">44</xref>,<xref rid="B132-vaccines-08-00621" ref-type="bibr">132</xref>].</p><p>Pulmonary administration was found to be an effective route for the delivery of a pertussis OMV vaccine and induced Th17 and Th1 responses locally in the lung and systemically, as well as antigen-specific IgA production [<xref rid="B136-vaccines-08-00621" ref-type="bibr">136</xref>]. However, pulmonary immunization did not prevent nasal colonization with <italic toggle="yes">B. pertussis</italic> [<xref rid="B136-vaccines-08-00621" ref-type="bibr">136</xref>]. In contrast, immunization with OMV by the i.n. but not the s.c. route conferred significant protection in the nasal cavity [<xref rid="B137-vaccines-08-00621" ref-type="bibr">137</xref>]. Protection was associated with the induction of mucosal IL-17 and IFN-&#947;, increased lung and nasal IgA as well as strong systemic Th17 responses [<xref rid="B137-vaccines-08-00621" ref-type="bibr">137</xref>].</p></sec><sec id="sec4dot3-vaccines-08-00621"><title>4.3. aP Vaccines with New Antigens</title><p>One explanation for the failure of aP vaccines to confer long lasting protection in immunized individuals, is the limited number of antigens, which results in a narrower range of <italic toggle="yes">B. pertussis</italic>-specific immune responses [<xref rid="B72-vaccines-08-00621" ref-type="bibr">72</xref>]. In addition, there is evidence that aP vaccines with a limited number of antigens may have facilitated immune selective pressure that has led to the emergence of PRN(&#8722;) strains of <italic toggle="yes">B. pertussis</italic> [<xref rid="B26-vaccines-08-00621" ref-type="bibr">26</xref>,<xref rid="B138-vaccines-08-00621" ref-type="bibr">138</xref>]. PRN(&#8722;) strains have been shown to outcompete PRN(+) strains in aP-immunized mice [<xref rid="B28-vaccines-08-00621" ref-type="bibr">28</xref>]. Strains with mutations in the promoter region of the <italic toggle="yes">ptx</italic> gene which encodes PT have also been identified [<xref rid="B139-vaccines-08-00621" ref-type="bibr">139</xref>]. <italic toggle="yes">B. pertussis</italic> strains lacking both PRN and PT are rarer, but have also been documented, as have reports of FHA and FIM2/3 deficient strains [<xref rid="B140-vaccines-08-00621" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-08-00621" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-08-00621" ref-type="bibr">142</xref>,<xref rid="B143-vaccines-08-00621" ref-type="bibr">143</xref>]. Therefore, addition of new antigens to aP vaccines may increase protection and reduce the effects of immune selective pressure. </p><p>FIM2/3 are currently included in five-component aP vaccines, but not in two- and three-component vaccines, and clinical trials have shown that aP vaccines which contain FIM2/3 may be more efficacious in preventing pertussis disease [<xref rid="B12-vaccines-08-00621" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-08-00621" ref-type="bibr">13</xref>]. Studies in mice showed that the addition of high doses of FIM2/3 to commercial, two-, three- and five-component aP vaccines increased protection in the lungs following challenge with a Prn(&#8722;) strain of <italic toggle="yes">B. pertussis</italic>.</p><p><italic toggle="yes">B. pertussis</italic> virulence is regulated by the BvgAS system, which includes two components, the histidine kinase, BvgS, and the response regulator BvgA [<xref rid="B144-vaccines-08-00621" ref-type="bibr">144</xref>]. The BvgAS system positively regulates almost all <italic toggle="yes">B. pertussis</italic> virulence factors, including current aP antigens PT, FHA, PRN and FIM2/3 [<xref rid="B145-vaccines-08-00621" ref-type="bibr">145</xref>]. Adenylate cyclase toxin (ACT) is encoded by the <italic toggle="yes">cyaA</italic> gene, activated by BvgA [<xref rid="B146-vaccines-08-00621" ref-type="bibr">146</xref>], and plays a central role in inhibiting the host immune response to <italic toggle="yes">B. pertussis</italic> and promotes bacterial survival [<xref rid="B147-vaccines-08-00621" ref-type="bibr">147</xref>]. Although ACT is an important <italic toggle="yes">B. pertussis</italic> virulence factor, it is not currently included in any commercial aP vaccine. Early evidence that ACT may be an immunodominant antigen came from studies showing that <italic toggle="yes">B. pertussis</italic>-infected individuals had high levels of anti-ACT antibodies [<xref rid="B148-vaccines-08-00621" ref-type="bibr">148</xref>]. Anti-ACT antibodies are also generated following immunization with wP vaccines and are present in newborn cord blood [<xref rid="B149-vaccines-08-00621" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-08-00621" ref-type="bibr">150</xref>]. Native and recombinant ACT have been shown to have protective function in animal models [<xref rid="B151-vaccines-08-00621" ref-type="bibr">151</xref>,<xref rid="B152-vaccines-08-00621" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-08-00621" ref-type="bibr">153</xref>,<xref rid="B154-vaccines-08-00621" ref-type="bibr">154</xref>]. Addition of active or enzymatically inactive ACT to aP vaccines promoted a shift from Th2 to a mixed Th1/Th2 response and enhanced protection against lung infection with <italic toggle="yes">B. pertussis</italic> in mice, however, immunization with ACT alone did not confer protection [<xref rid="B155-vaccines-08-00621" ref-type="bibr">155</xref>]. ACT in its native form, undergoes quick proteolytic degradation within the cell, complicating its potential use in aP vaccines [<xref rid="B156-vaccines-08-00621" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-08-00621" ref-type="bibr">157</xref>]. However, RTX antigens, which are more stable than full-length ACT generate strong ACT neutralizing antibody responses [<xref rid="B158-vaccines-08-00621" ref-type="bibr">158</xref>]. Addition of C-terminal repeats-in-toxin domain (RTX) of ACT to a low dose (1/80 of human dose) of an aP vaccine enhanced its protective efficacy against lung infection with <italic toggle="yes">B. pertussis</italic> in mice [<xref rid="B159-vaccines-08-00621" ref-type="bibr">159</xref>].</p><p>Bordetella resistance to killing A (BrkA), a virulence factor activated by phosphorylated BvgA, which has autotransporter function and plays a role in bacterial adherence to lung epithelial cells, as well as in evading complement-mediated phagocytosis [<xref rid="B160-vaccines-08-00621" ref-type="bibr">160</xref>] is another candidate antigen that may improve the efficacy of aP vaccines. Immunization of mice with BrkA alone by the s.c. route did not confer protection against lung infection in mice, but it did enhance protection when added to an aP vaccine comprising FHA and PT antigens [<xref rid="B161-vaccines-08-00621" ref-type="bibr">161</xref>]. However, another study showed that when compared with control mice immunized with alum only, mice immunization with an alum-adjuvanted mono-component BrkA vaccine by the i.p. route had lower numbers of bacteria in the lungs 7 days post <italic toggle="yes">B. pertussis</italic> challenge [<xref rid="B162-vaccines-08-00621" ref-type="bibr">162</xref>].</p><p>Immunization by the s.c. route with either recombinant BvgA-activated autotransporter, Vag8 or SphB1, adjuvanted with alum conferred some protection against lung infection with <italic toggle="yes">B. pertussis</italic> B1917. However, vaccines containing these antigens did not confer protection in the upper respiratory tract [<xref rid="B163-vaccines-08-00621" ref-type="bibr">163</xref>]. Although the addition of new antigens may indeed enhance protection in the lung, it is evident that generating protection in the upper respiratory tract will prove more challenging and may not be achievable solely through the addition of antigens to parenterally administered aP vaccines.</p></sec><sec id="sec4dot4-vaccines-08-00621"><title>4.4. aP Vaccines with New Adjuvants</title><p>Adjuvants function by activating innate immune cells, which in turn direct adaptive immune responses to antigenic components in a vaccine, and this not only increases the quantity of the immune response but can improve its quality [<xref rid="B164-vaccines-08-00621" ref-type="bibr">164</xref>]. Natural components of many live attenuated and killed whole-cell vaccines have adjuvant properties, but this can result in excessive unwanted inflammation, as observed in some instances with wP vaccines [<xref rid="B4-vaccines-08-00621" ref-type="bibr">4</xref>,<xref rid="B165-vaccines-08-00621" ref-type="bibr">165</xref>]. Subunit vaccines, on the other hand, are often poorly immunogenic without the addition of an appropriate adjuvant [<xref rid="B166-vaccines-08-00621" ref-type="bibr">166</xref>]. Live <italic toggle="yes">B. pertussis</italic> and wP vaccines contain LPS, which activates DCs through TLR4, and although effective in eliciting strong Th1 and Th17 responses, LPS is not a safe adjuvant for human use [<xref rid="B93-vaccines-08-00621" ref-type="bibr">93</xref>,<xref rid="B167-vaccines-08-00621" ref-type="bibr">167</xref>]. However, there are a number of alternative adjuvants based on PAMPs, including TLR agonists, and particulate delivery systems that are safe for use in humans (<xref ref-type="fig" rid="vaccines-08-00621-f002">Figure 2</xref>).</p><sec id="sec4dot4dot1-vaccines-08-00621"><title>4.4.1. Alum</title><p>All licensed aP vaccines utilize alum as the adjuvant. Alum has been in common use since the 1920s, when it was first shown to enhance immunogenicity of diphtheria toxoid [<xref rid="B168-vaccines-08-00621" ref-type="bibr">168</xref>]. Alum or aluminum salts are safe and non-toxic adjuvants, and promote strong antibody and Th2 response, but also induce IL-10 production by DCs and macrophages, which can inhibit polarization of Th1 cells [<xref rid="B169-vaccines-08-00621" ref-type="bibr">169</xref>] Its beneficial role was initially believed to be due to depot formation, where antigens are sequestered within an alum aggregate at the site of injection, allowing slow release of antigens [<xref rid="B170-vaccines-08-00621" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-08-00621" ref-type="bibr">171</xref>]. Furthermore, the particulate antigens generated with alum can be phagocytosed more readily by APCs [<xref rid="B172-vaccines-08-00621" ref-type="bibr">172</xref>]. Alum can also activate the NLRP3 inflammasome, leading to IL-1&#946; processing [<xref rid="B173-vaccines-08-00621" ref-type="bibr">173</xref>,<xref rid="B174-vaccines-08-00621" ref-type="bibr">174</xref>] and this can promote the generation of Th17 responses in mice immunized with aP vaccines [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>]. Other studies have shown that NLRP3 may be dispensable for its activity as an adjuvant, suggesting multiple mechanisms of immune activation [<xref rid="B175-vaccines-08-00621" ref-type="bibr">175</xref>].</p><p>Alum can inhibit IL-12 production by DCs thereby generating Th2-skewed CD4 T cell responses [<xref rid="B176-vaccines-08-00621" ref-type="bibr">176</xref>]. Th2 polarization along with strong antibody responses are effective for vaccines against certain infectious diseases, where their protection clearly correlates with humoral immunity [<xref rid="B177-vaccines-08-00621" ref-type="bibr">177</xref>]. However, this may not be the case for pertussis, where there is a clear protective role for T cells. An alternative strategy for inducing protective cellular immune responses and memory is through the addition of novel adjuvants to aP vaccines, either replacing alum completely, or adding them to vaccines already formulated with alum.</p></sec><sec id="sec4dot4dot2-vaccines-08-00621"><title>4.4.2. TLR4 Agonists</title><p>The TLR4 agonist LPS is a natural component of the outer membrane of <italic toggle="yes">B. pertussis</italic> and is present in wP vaccines, functioning as a natural adjuvant, which contributes to protective immunity induced with this vaccine [<xref rid="B93-vaccines-08-00621" ref-type="bibr">93</xref>,<xref rid="B178-vaccines-08-00621" ref-type="bibr">178</xref>]. TLR4 signaling is crucial for early innate responses and airway neutrophil recruitment during <italic toggle="yes">B. pertussis</italic> infection, and is essential for protection generated with the BPZE1 vaccine [<xref rid="B126-vaccines-08-00621" ref-type="bibr">126</xref>,<xref rid="B179-vaccines-08-00621" ref-type="bibr">179</xref>]. LPS is a potent activator of TLR4-dependent pro-inflammatory responses, but because of its toxicity is not safe for use as an adjuvant for human subunit vaccines [<xref rid="B180-vaccines-08-00621" ref-type="bibr">180</xref>]. To overcome toxicity issue while retaining its adjuvant capacity, LPS derivatives, such as monophosphoryl lipid-A (MPL), have been developed which can bind TLR4, and induce downstream signaling without the risk of adverse events [<xref rid="B181-vaccines-08-00621" ref-type="bibr">181</xref>]. MPL is an approved adjuvant in vaccines against hepatitis B virus and human papilloma virus [<xref rid="B182-vaccines-08-00621" ref-type="bibr">182</xref>,<xref rid="B183-vaccines-08-00621" ref-type="bibr">183</xref>]. Mice immunized with an aP vaccine formulated with MPL had lower bacterial load in the lung post <italic toggle="yes">B. pertussis</italic> challenge, compared to mice immunized with alum-adjuvanted aP [<xref rid="B184-vaccines-08-00621" ref-type="bibr">184</xref>]. These mice also had higher anti-PT IgG in serum, and reduced <italic toggle="yes">B. pertussis</italic>-specific Th2 responses [<xref rid="B184-vaccines-08-00621" ref-type="bibr">184</xref>].</p><p>An alternative LPS derivative from <italic toggle="yes">Neisseria meningitis</italic>, LpxL2, promoted protective immunity comparable to MPL. The aP vaccines formulated with MPL or LpxL2 induced less IL-6 production in mice than a wP vaccine, suggesting that they may promote protective inflammatory response with a reduced risk of immunopathology [<xref rid="B184-vaccines-08-00621" ref-type="bibr">184</xref>]. The LPS derivative, LpxL1, also derived from <italic toggle="yes">N. meningitis</italic>, has been shown to shift CD4 T cell responses from a Th2 to Th1/Th17 profile in mice when added to a commercial alum-adjuvanted aP vaccine [<xref rid="B185-vaccines-08-00621" ref-type="bibr">185</xref>]. Using MHC class II PRN tetramers, the authors showed that the addition of LpxL1 to aP vaccine led to increased PRN-specific CD4 T cells and a greater number of T cells with a T<sub>CM</sub> phenotype in the draining lymph nodes and blood of immunized mice [<xref rid="B185-vaccines-08-00621" ref-type="bibr">185</xref>]. Transcriptomic analysis revealed that genes involved in Th2 and Treg polarization were upregulated in mice immunized with the aP vaccine alone, whereas the addition of LpxL1 to an aP vaccine led to an increase in <italic toggle="yes">il17</italic> and <italic toggle="yes">ifn&#947;</italic> mRNA expression, as well as increasing expression of Th1 and Th17 transcription factor genes, <italic toggle="yes">tbx21</italic> and <italic toggle="yes">rorc</italic>. This demonstrates how the addition of a TLR4 agonist can alter immune responses at a gene expression level [<xref rid="B186-vaccines-08-00621" ref-type="bibr">186</xref>].</p></sec><sec id="sec4dot4dot3-vaccines-08-00621"><title>4.4.3. TLR 9 Agonists</title><p>Unmethylated single-stranded CpG DNA motifs, which are released from bacteria during infection, activate TLR9 signaling [<xref rid="B187-vaccines-08-00621" ref-type="bibr">187</xref>]. Synthetic CpG oligodeoxynucleotides (ODNs) that mimic this process have adjuvant capacity, generate strong Th1 responses in mice and humans and are capable of overriding the alum-driven Th2 bias when used in combination with alum [<xref rid="B188-vaccines-08-00621" ref-type="bibr">188</xref>,<xref rid="B189-vaccines-08-00621" ref-type="bibr">189</xref>,<xref rid="B190-vaccines-08-00621" ref-type="bibr">190</xref>]. The addition of CpG ODNs to an aP vaccine, either with or without alum, increased anti-PT IgG2a serum antibody titers [<xref rid="B191-vaccines-08-00621" ref-type="bibr">191</xref>] and robustly induce IFN-&#947;-producing splenic T cells [<xref rid="B192-vaccines-08-00621" ref-type="bibr">192</xref>]. Ross et al. showed that an experimental aP vaccine formulated with CpG alone induced <italic toggle="yes">B. pertussis</italic>-specific Th1 and Th17 responses, and IgG2 antibody responses in mice [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>]. This was associated with significant protection against lung infection with <italic toggle="yes">B. pertussis</italic>, with full clearance of bacteria by day 10 post challenge, compared with day 15 for mice immunized with an aP vaccine formulated with alum [<xref rid="B16-vaccines-08-00621" ref-type="bibr">16</xref>].</p><p>A study by Asokanathan and colleagues demonstrated that addition of CpG to an alum-adjuvanted aP vaccine enhanced protection against lung infection of mice with <italic toggle="yes">B. pertussis.</italic> This was associated with increased IFN-&#947; production in the spleen and increased nitric oxide production in peritoneal macrophages stimulated in vitro with heat-killed <italic toggle="yes">B. pertussis</italic> [<xref rid="B190-vaccines-08-00621" ref-type="bibr">190</xref>]. However, in this study, substituting CpG for alum did not enhance protection against lung infection.</p></sec><sec id="sec4dot4dot4-vaccines-08-00621"><title>4.4.4. TLR7 Agonists</title><p>TLR7 agonists have adjuvant activity, enhance vaccine efficacy and generate Th1/Th17 responses in a number of infectious diseases [<xref rid="B193-vaccines-08-00621" ref-type="bibr">193</xref>,<xref rid="B194-vaccines-08-00621" ref-type="bibr">194</xref>,<xref rid="B195-vaccines-08-00621" ref-type="bibr">195</xref>]. The adsorption of small molecule TLR7 agonists to alum increases their safety for use as adjuvants, due to reduced systemic inflammation and attenuated cytokine release into the blood, while also improving adjuvant function [<xref rid="B196-vaccines-08-00621" ref-type="bibr">196</xref>]. Addition of the synthetic TLR7 agonist, SMIP-7.10 to an alum-absorbed aP vaccine significantly enhanced its efficacy and conferred protection against lung infection of mice with <italic toggle="yes">B. pertussis</italic>, comparable to that generated with a wP vaccine [<xref rid="B197-vaccines-08-00621" ref-type="bibr">197</xref>]. The addition of SMIP-7.10 resulted in a shift from a Th2 response induced with the alum-adjuvanted vaccine to the induction of Th1 and Th17 responses. This was accompanied by an increase in IgG2a and IgG2c antibodies as well as enhanced functional activity, including antibodies that neutralized PT and inhibited FHA binding to human lung epithelial cells [<xref rid="B197-vaccines-08-00621" ref-type="bibr">197</xref>]. These findings suggest that it may be possible to enhance the efficacy of existing alum-adjuvanted aP vaccines by addition of small molecule TLR agonists that promote protective T cell responses.</p></sec><sec id="sec4dot4dot5-vaccines-08-00621"><title>4.4.5. TLR2 Agonists</title><p><italic toggle="yes">B. pertussis</italic> expresses a number of lipoproteins that are TLR2 agonists and also have antigenic properties [<xref rid="B198-vaccines-08-00621" ref-type="bibr">198</xref>]. BP1569 and a synthetic lipopeptide derivative LP1569 have immunomodulatory activity, activating innate immune responses and acted as adjuvants for an experimental aP vaccine in mice. LP1569 induced the production of T cell polarising cytokines, IL-1&#946;, IL-12, IL-23 and enhanced expression of costimulatory molecules, CD80 and CD86, and MHC class II on murine and human DCs [<xref rid="B198-vaccines-08-00621" ref-type="bibr">198</xref>]. Immunization of mice with an aP vaccine formulated with LP1569 enhanced protection against lung and trachea infection compared with an alum-adjuvanted aP vaccine [<xref rid="B198-vaccines-08-00621" ref-type="bibr">198</xref>]. Furthermore, strong FHA-specific Th1 and Th17 responses were observed in spleen of mice immunized with the aP vaccine formulated with LP1569, whereas strong Th2 responses were observed in mice immunized with <italic toggle="yes">B. pertussis</italic> antigens alone or with alum [<xref rid="B198-vaccines-08-00621" ref-type="bibr">198</xref>].</p></sec><sec id="sec4dot4dot6-vaccines-08-00621"><title>4.4.6. STING and TLR Agonists</title><p>Stimulator of interferon genes (STING), which binds cyclic dinucleotides (CDNs), functions as an adaptor molecule for the cytosolic DNA receptor cyclic-GMP-AMP synthase (cGAS), which converts double-stranded (ds)DNA to the second messenger, cyclic GMP-AMP (cGAMP) [<xref rid="B199-vaccines-08-00621" ref-type="bibr">199</xref>]. STING acts as a PRR and detects bacterial second messengers, such as cyclic-di-GMP (c-di-GMP) and c-di-AMP (c-di-AMP) [<xref rid="B200-vaccines-08-00621" ref-type="bibr">200</xref>,<xref rid="B201-vaccines-08-00621" ref-type="bibr">201</xref>]. Ligation of STING by CDNs activates signaling pathways leading to the activation of the transcription factors NF-&#954;B and IRF3 and type 1 interferon gene expression [<xref rid="B202-vaccines-08-00621" ref-type="bibr">202</xref>,<xref rid="B203-vaccines-08-00621" ref-type="bibr">203</xref>].</p><p>Administration of c-di-GMP to mice by the i.n. route 24 h before <italic toggle="yes">B. pertussis</italic> challenge enhanced bacterial clearance from the lungs of mice [<xref rid="B204-vaccines-08-00621" ref-type="bibr">204</xref>]. C-di-GMP treatment increased pulmonary neutrophil and macrophage recruitment and induced early macrophage inflammatory protein-2 (MIP-2), which is important for neutrophil recruitment, and macrophage chemotactic protein 1 (MCP-1), which recruits a range of lymphoid and myeloid cells [<xref rid="B204-vaccines-08-00621" ref-type="bibr">204</xref>,<xref rid="B205-vaccines-08-00621" ref-type="bibr">205</xref>,<xref rid="B206-vaccines-08-00621" ref-type="bibr">206</xref>,<xref rid="B207-vaccines-08-00621" ref-type="bibr">207</xref>]. DC activation and Th1 cytokine production was also enhanced before and after <italic toggle="yes">B. pertussis</italic> challenge in mice treated with c-di-GMP [<xref rid="B204-vaccines-08-00621" ref-type="bibr">204</xref>]. These findings demonstrated the central role of innate immune stimulation in generating a protective immunity against <italic toggle="yes">B. pertussis</italic> and suggested that c-di-GMP could be a viable adjuvant for a pertussis vaccine.</p><p>The adjuvant activity of STING agonists is enhanced when combined with TLR agonists. The combination of agonists for STING and TLR2 or TLR9 induced IL-12 and IL-23 production by innate immune cells, which promoted induction of Th1 and Th17 cells [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>,<xref rid="B208-vaccines-08-00621" ref-type="bibr">208</xref>]. The STING agonist c-di-GMP combined with the TLR2 agonist LP1569, termed LP-GMP, has potent adjuvant activity and when added to an experimental 3-component aP vaccine, containing FHA, PT and PRN, promoted protective immunity against <italic toggle="yes">B. pertussis</italic> in the lower and upper respiratory tract of mice [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>]. The most dramatic adjuvant effect was observed when LP-GMP-adjuvanted aP was administered by the i.n. route; this combination conferred sustained protection against nasal colonization and lung infection of mice when challenged with <italic toggle="yes">B. pertussis</italic> up to 10 months after immunization [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>]. In contrast, the same aP vaccine formulated with alum did not confer any protection against nasal colonization [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>,<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>]. The aP vaccine formulated with LP-GMP induced potent Th17 responses, especially when delivered by the i.n. route. However, parenteral immunization generated stronger systemic <italic toggle="yes">B. pertussis</italic>-specific IFN-&#947;, indicating stronger Th1 responses [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>]. Immunization with LP-GMP-formulated aP vaccine also promoted accumulation of CD69<sup>+</sup> CD103<sup>+/-</sup> CD4 T<sub>RM</sub> cells in the lung and nasal tissue; induction of respiratory T<sub>RM</sub> cells was most effective following i.n. administration of the vaccine. These respiratory T<sub>RM</sub> cells predominantly produced IL-17 and the number of these cells strongly correlated with long-term protective immunity in the nasal cavity [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>]. This highlights the potential power of combining adjuvants to generate a robust Th1/Th17 response and T<sub>RM</sub> cells, and demonstrates how mucosal immunization can further enhance protective immunity in the respiratory tract.</p></sec><sec id="sec4dot4dot7-vaccines-08-00621"><title>4.4.7. Particulate Antigen Delivery Systems, Live Vectors and Nucleic Acid Vaccines</title><p>Vaccine delivery vehicles have also been used as tools to improve the efficacy of pertussis vaccines. Microparticles made from the biodegradable polymer poly(lactide-co-glycolide) (PLG) have been utilized as a delivery vehicle for aP vaccines. A single parenteral dose of PLG microparticle-encapsulated FHA and detoxified PT was shown to induce robust Th1 responses and to protect against <italic toggle="yes">B. pertussis</italic> infection in the lungs of mice [<xref rid="B209-vaccines-08-00621" ref-type="bibr">209</xref>]. Liposomes also have potential as particulate delivery systems for aP vaccines, having already shown promise in experimental vaccines against other infectious diseases, notably <italic toggle="yes">Mycobacterium tuberculosis</italic> [<xref rid="B210-vaccines-08-00621" ref-type="bibr">210</xref>]. Furthermore, recombinant vector vaccines and mRNA and DNA vaccines are in development for viruses such as SARS-CoV-2 [<xref rid="B211-vaccines-08-00621" ref-type="bibr">211</xref>] and have potential in the development of new vaccines against <italic toggle="yes">B. pertussis</italic>.</p></sec></sec></sec><sec id="sec5-vaccines-08-00621"><title>5. Route of Vaccine Administration&#8212;A Case for an Intranasal Pertussis Vaccine</title><p>Most vaccines approved for use in humans are delivered via parenteral routes, mostly intramuscular (i.m.), but also s.c. or intradermal (i.d.) [<xref rid="B212-vaccines-08-00621" ref-type="bibr">212</xref>]. It is now evident that pathogens that infect mucosal surfaces require effective local immunity and immune memory at the mucosal site of infection. Recent studies in mouse models have demonstrated that the induction of mucosal T<sub>RM</sub> cells is key to sustained protective immunity against many mucosal pathogens, and immunization at mucosal site of infection appears to be the most effective strategy to achieve this [<xref rid="B213-vaccines-08-00621" ref-type="bibr">213</xref>]. Currently, the only approved mucosal vaccines are a live attenuated influenza vaccine delivered by nasal spray and a number of oral vaccines against enteric pathogens [<xref rid="B214-vaccines-08-00621" ref-type="bibr">214</xref>].</p><p>Studies that examined the route of administration of TB vaccines have demonstrated that efficacy is often enhanced when a vaccine is delivered by a mucosal route [<xref rid="B215-vaccines-08-00621" ref-type="bibr">215</xref>,<xref rid="B216-vaccines-08-00621" ref-type="bibr">216</xref>,<xref rid="B217-vaccines-08-00621" ref-type="bibr">217</xref>,<xref rid="B218-vaccines-08-00621" ref-type="bibr">218</xref>,<xref rid="B219-vaccines-08-00621" ref-type="bibr">219</xref>]. Protection against <italic toggle="yes">M. tuberculosis</italic> conferred by the attenuated <italic toggle="yes">M. bovis</italic> vaccine BCG is more effective following i.n. or intratracheal (i.t.) delivery compared with parenteral administration [<xref rid="B220-vaccines-08-00621" ref-type="bibr">220</xref>,<xref rid="B221-vaccines-08-00621" ref-type="bibr">221</xref>,<xref rid="B222-vaccines-08-00621" ref-type="bibr">222</xref>]. Mucosal immunization of mice with BCG induces a higher frequency of CD4 T<sub>RM</sub> cells in the lungs when compared with immunization by a parenteral route, and this is associated with enhanced protection against infection in the lungs [<xref rid="B215-vaccines-08-00621" ref-type="bibr">215</xref>,<xref rid="B216-vaccines-08-00621" ref-type="bibr">216</xref>].</p><p>In the context of <italic toggle="yes">B. pertussis</italic> infection, it is now established that generating strong mucosal responses in the lung and nasal cavity, including the generation of respiratory T<sub>RM</sub> cells, local IL-17 and sIgA are important for sustained protection against lung infection and nasal colonization [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B32-vaccines-08-00621" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>,<xref rid="B131-vaccines-08-00621" ref-type="bibr">131</xref>]. However, parenterally delivered alum-adjuvanted aP vaccines do not generate local immunity in the respiratory tract, but instead rely on circulating antibodies driven by systemic T cell responses to prevent severe disease mediated by the <italic toggle="yes">B. pertussis</italic> toxins [<xref rid="B14-vaccines-08-00621" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00621" ref-type="bibr">15</xref>,<xref rid="B29-vaccines-08-00621" ref-type="bibr">29</xref>,<xref rid="B223-vaccines-08-00621" ref-type="bibr">223</xref>]. Delivery of pertussis vaccines by the i.n. route has the potential to enhance local immune responses in the nasopharynx, and may provide a solution to the problem of asymptomatic colonization and transmission of <italic toggle="yes">B. pertussis</italic> [<xref rid="B224-vaccines-08-00621" ref-type="bibr">224</xref>]. The live attenuated vaccine, BPZE1, was specifically developed to be administered by the i.n. route and animal studies have shown that it can generate protective T<sub>RM</sub> cells that produce IL-17 and IFN-&#947;, as well as local sIgA in the respiratory tract, and can confer durable protection against nasal colonization with <italic toggle="yes">B. pertussis</italic> [<xref rid="B34-vaccines-08-00621" ref-type="bibr">34</xref>,<xref rid="B92-vaccines-08-00621" ref-type="bibr">92</xref>,<xref rid="B121-vaccines-08-00621" ref-type="bibr">121</xref>,<xref rid="B123-vaccines-08-00621" ref-type="bibr">123</xref>]. The first-in-human trials showed that the i.n. administration of BPZE1 is safe [<xref rid="B122-vaccines-08-00621" ref-type="bibr">122</xref>], and it is now being assessed in Phase 2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03541499">NCT03541499</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03942406">NCT03942406</ext-link>).</p><p>A pertussis OMV vaccine delivered by the i.n. route generated superior protection and stronger Th1/Th17 response compared with parenteral administration of the same vaccine [<xref rid="B137-vaccines-08-00621" ref-type="bibr">137</xref>]. Delivery of aP vaccines by the i.n. route also has the capacity to enhance the efficacy of aP vaccines, especially when formulated with adjuvants that stimulate local immunity in the respiratory tract. We have reported that i.n. administration of a three-component aP vaccine, adjuvanted combined with the potent T cell-inducing adjuvant LP-GMP promoted induction of IL-17<sup>+</sup> T<sub>RM</sub> cells in the lungs and nasal tissue and conferred long-lived protection against nasal colonization as well as lung infection [<xref rid="B33-vaccines-08-00621" ref-type="bibr">33</xref>].</p></sec><sec id="sec6-vaccines-08-00621"><title>6. Concluding Remarks</title><p>Great strides have been made in recent years on our understanding of the mechanisms of protective immunity against <italic toggle="yes">B. pertussis</italic>, which will assist in the design of next generation pertussis vaccines. Most people in the field now accept that the current alum-adjuvanted patenterally-delivered aP vaccine is suboptimal and needs to be supplemented or replaced with a more effective pertussis vaccine. The discovery from baboon and mouse models that current aP vaccines do not generate protective immunity against nasal colonization has been a game-changer. Together with epidemiological studies in humans, the findings suggest asymptomatic transmission is occurring in vaccinated populations. The demonstration that the current aP vaccines fail to generate CD4 T<sub>RM</sub> cells in the lung and nasal tissue, alongside the well-established fact that they do not induce mucosal IgA, has focused attention on the need for new vaccine approaches that induce local T cells and antibodies in the respiratory tract. There is strong evidence that IFN-&#947;-secreting Th1 cells play a key role in clearance of a primary infection and preventing re-infection of the lungs with <italic toggle="yes">B. pertussis</italic>. In contrast, protection in the nasal cavity appears to be more dependent on IL-17 produced by Th17 and possibly also from other sources, including &#947;&#948; T cells.</p><p>The induction of potent Th1- and Th17-type CD4 T<sub>RM</sub> cells is likely to be a key factor in the design of more effective vaccines. The use of novel adjuvants and vaccine delivery systems in aP vaccines, as well as the development of live attenuated and OMV vaccines for pertussis, are already showing promising results in animal models and more limited early clinical trials. The implementation of new vaccines will not be straightforward, as unbundling of the current pediatric combination would be logistically difficult. The first steps may see the implementation of new booster vaccines involving the existing aP vaccine antigens but with a novel adjuvant. However, emerging data suggest that it may not be easy to shift the Th2 responses set following immunization with current alum-adjuvanted aP vaccine. Therefore, an alternative approach may be to introduce a priming dose with stand-alone pertussis vaccine formulation that induces the desired cellular immune responses in neonates. If <italic toggle="yes">B. pertussis</italic>-specific Th1 and Th17 responses are set early in life prior to immunization with routine pediatric vaccine (including pertussis) formulated with alum, this may be the road to a more effective vaccine that will induce sterilizing immunity in the nasal cavity as well as the lungs. However, a longer term objective, which is likely to be more effective, should be to remove the aP vaccine from the current pediatric combination and replace it with an easily administered nasally-delivered pertussis vaccine, which promotes respiratory T<sub>RM</sub> cells that confer sustained protective immunity in the nasal mucosae as well as the lungs.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Lisa Borkner, Pauline Schmitt and Mieszko Wilk for helpful comments on the manuscript.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>C.N.C. and K.H.G.M.; writing, review and editing, K.H.G.M.; funding acquisition. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by Science Foundation Ireland (grant number 16/IA/4468) and the Irish Research Council (grant number GOIPG/2020/1241).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Kingston Mills is inventor on a patent application on <italic toggle="yes">B. pertussis</italic>-derived TLR2 agonists as novel adjuvants and has collaborative research funding from and acts as consultant to Vaccine manufacturers. The funders had no role in the writing of the manuscript or in the decision to publish this review.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-08-00621"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>J.D.</given-names></name></person-group><article-title>Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies</article-title><source>Clin. Microbiol. Rev.</source><year>2005</year><volume>18</volume><fpage>326</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1128/CMR.18.2.326-382.2005</pub-id><pub-id pub-id-type="pmid">15831828</pub-id><pub-id pub-id-type="pmcid">PMC1082800</pub-id></element-citation></ref><ref id="B2-vaccines-08-00621"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hewlett</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Harvill</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Stibitz</surname><given-names>E.S.</given-names></name></person-group><article-title>Pertussis Pathogenesis&#8212;What We Know and What We Don&#8217;t Know</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>209</volume><fpage>982</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit639</pub-id><pub-id pub-id-type="pmid">24626533</pub-id><pub-id pub-id-type="pmcid">PMC3952676</pub-id></element-citation></ref><ref id="B3-vaccines-08-00621"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janda</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Celig</surname><given-names>D.</given-names></name><name name-style="western"><surname>Terrile</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schreckenberger</surname><given-names>P.C.</given-names></name></person-group><article-title>Unexpected isolation of Bordetella pertussis from a blood culture</article-title><source>J. Clin. Microbiol.</source><year>1994</year><volume>32</volume><fpage>2851</fpage><lpage>2853</lpage><pub-id pub-id-type="doi">10.1128/JCM.32.11.2851-2853.1994</pub-id><pub-id pub-id-type="pmid">7852585</pub-id><pub-id pub-id-type="pmcid">PMC264173</pub-id></element-citation></ref><ref id="B4-vaccines-08-00621"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cody</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Baraff</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Marcy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Manclark</surname><given-names>C.R.</given-names></name></person-group><article-title>Nature and Rates of Adverse Reactions Associated with DTP and DT Immunizations in Infants and Children</article-title><source>Pediatrics</source><year>1981</year><volume>68</volume><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">7031583</pub-id></element-citation></ref><ref id="B5-vaccines-08-00621"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decker</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Steinhoff</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rennels</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Pichichero</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Deloria</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>G.F.</given-names></name></person-group><article-title>Comparison of 13 acellular pertussis vaccines: Adverse reactions</article-title><source>Pediatrics</source><year>1995</year><volume>96</volume><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">7659476</pub-id></element-citation></ref><ref id="B6-vaccines-08-00621"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>K.M.</given-names></name></person-group><article-title>Unraveling the challenges of pertussis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>575</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1073/pnas.1321360111</pub-id><pub-id pub-id-type="pmid">24381159</pub-id><pub-id pub-id-type="pmcid">PMC3896212</pub-id></element-citation></ref><ref id="B7-vaccines-08-00621"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorringe</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>T.E.</given-names></name></person-group><article-title>Bordetella pertussis fimbriae (Fim): Relevance for vaccines</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>1205</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.930667</pub-id><pub-id pub-id-type="pmid">25102891</pub-id></element-citation></ref><ref id="B8-vaccines-08-00621"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Meade</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Rennels</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Steinhoff</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pichichero</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Deloria</surname><given-names>M.A.</given-names></name></person-group><article-title>Comparison of 13 acellular pertussis vaccines: Overview and serologic response</article-title><source>Pediatrics</source><year>1995</year><volume>96</volume><fpage>548</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">7659475</pub-id></element-citation></ref><ref id="B9-vaccines-08-00621"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Pertussis vaccines: WHO position paper, August 2015&#8212;Recommendations</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>1423</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.10.136</pub-id><pub-id pub-id-type="pmid">26562318</pub-id></element-citation></ref><ref id="B10-vaccines-08-00621"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broder</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Iskander</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kretsinger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Slade</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Mijalski</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title><source>MMWR Recomm. Rep.</source><year>2006</year><volume>55</volume><fpage>1</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16557217</pub-id></element-citation></ref><ref id="B11-vaccines-08-00621"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>L.C.</given-names></name></person-group><article-title>Pertussis Vaccine Trials in the 1990s</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>209</volume><fpage>S4</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit592</pub-id><pub-id pub-id-type="pmid">24626871</pub-id><pub-id pub-id-type="pmcid">PMC3968808</pub-id></element-citation></ref><ref id="B12-vaccines-08-00621"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hallander</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Heijbel</surname><given-names>H.</given-names></name></person-group><article-title>Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>1569</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)06508-2</pub-id><pub-id pub-id-type="pmid">9393335</pub-id></element-citation></ref><ref id="B13-vaccines-08-00621"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gustafsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hallander</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Olin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reizenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Storsaeter</surname><given-names>J.</given-names></name></person-group><article-title>A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine</article-title><source>N. Engl. J. Med.</source><year>1996</year><volume>334</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1056/NEJM199602083340602</pub-id><pub-id pub-id-type="pmid">8538705</pub-id></element-citation></ref><ref id="B14-vaccines-08-00621"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warfel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>T.J.</given-names></name></person-group><article-title>Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>787</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1073/pnas.1314688110</pub-id><pub-id pub-id-type="pmid">24277828</pub-id><pub-id pub-id-type="pmcid">PMC3896208</pub-id></element-citation></ref><ref id="B15-vaccines-08-00621"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Borkner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curham</surname><given-names>L.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Immunization with whole cell but not acellular pertussis vaccines primes CD4 T RM cells that sustain protective immunity against nasal colonization with Bordetella pertussis</article-title><source>Emerg. Microbes Infect.</source><year>2019</year><volume>8</volume><fpage>169</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1080/22221751.2018.1564630</pub-id><pub-id pub-id-type="pmid">30866771</pub-id><pub-id pub-id-type="pmcid">PMC6455184</pub-id></element-citation></ref><ref id="B16-vaccines-08-00621"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003264</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003264</pub-id><pub-id pub-id-type="pmid">23592988</pub-id><pub-id pub-id-type="pmcid">PMC3617212</pub-id></element-citation></ref><ref id="B17-vaccines-08-00621"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>T.J.</given-names></name></person-group><article-title>Pertussis vaccines and protective immunity</article-title><source>Curr. Opin. Immunol.</source><year>2019</year><volume>59</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2019.03.006</pub-id><pub-id pub-id-type="pmid">31078081</pub-id><pub-id pub-id-type="pmcid">PMC6774807</pub-id></element-citation></ref><ref id="B18-vaccines-08-00621"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arsenault</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nandi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mendoza Rodr&#237;guez</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>S.</given-names></name></person-group><article-title>Country-level predictors of vaccination coverage and inequalities in Gavi-supported countries</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>2479</fpage><lpage>2488</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.029</pub-id><pub-id pub-id-type="pmid">28365251</pub-id></element-citation></ref><ref id="B19-vaccines-08-00621"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobanjo-ter Meulen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duclos</surname><given-names>P.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>K.D.C.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Klugman</surname><given-names>K.P.</given-names></name></person-group><article-title>Assessing the Evidence for Maternal Pertussis Immunization: A Report From the Bill &amp; Melinda Gates Foundation Symposium on Pertussis Infant Disease Burden in Low- and Lower-Middle-Income Countries</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>S123</fpage><lpage>S133</lpage><pub-id pub-id-type="pmid">27838664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw530</pub-id><pub-id pub-id-type="pmcid">PMC5106619</pub-id></element-citation></ref><ref id="B20-vaccines-08-00621"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diavatopoulos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kampmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Silerova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heininger</surname><given-names>U.</given-names></name><name name-style="western"><surname>van Dongen</surname><given-names>J.J.M.</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Huijnen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Siena</surname><given-names>E.</given-names></name><etal/></person-group><article-title>PERISCOPE: Road towards effective control of pertussis</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>e179</fpage><lpage>e186</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30646-7</pub-id><pub-id pub-id-type="pmid">30503084</pub-id></element-citation></ref><ref id="B21-vaccines-08-00621"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fireman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rowhani-Rahbar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>R.</given-names></name></person-group><article-title>Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers</article-title><source>Pediatrics</source><year>2013</year><volume>131</volume><fpage>e1716</fpage><lpage>e1722</lpage><pub-id pub-id-type="doi">10.1542/peds.2012-3836</pub-id><pub-id pub-id-type="pmid">23690518</pub-id></element-citation></ref><ref id="B22-vaccines-08-00621"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheridan</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Ware</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Grimwood</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>S.B.</given-names></name></person-group><article-title>Number and order of whole cell pertussis vaccines in infancy and disease protection</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>454</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.6364</pub-id><pub-id pub-id-type="pmid">22851107</pub-id></element-citation></ref><ref id="B23-vaccines-08-00621"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowhani-Rahbar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fireman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>R.</given-names></name></person-group><article-title>Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1012</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200850</pub-id><pub-id pub-id-type="pmid">22970945</pub-id></element-citation></ref><ref id="B24-vaccines-08-00621"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harriman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zipprich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schechter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Talarico</surname><given-names>J.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chavez</surname><given-names>G.</given-names></name></person-group><article-title>California Pertussis Epidemic, 2010</article-title><source>J. Pediatr.</source><year>2012</year><volume>161</volume><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2012.05.041</pub-id><pub-id pub-id-type="pmid">22819634</pub-id></element-citation></ref><ref id="B25-vaccines-08-00621"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fireman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>R.</given-names></name></person-group><article-title>Waning Tdap Effectiveness in Adolescents</article-title><source>Pediatrics</source><year>2016</year><volume>137</volume><fpage>e20153326</fpage><pub-id pub-id-type="doi">10.1542/peds.2015-3326</pub-id><pub-id pub-id-type="pmid">26908667</pub-id></element-citation></ref><ref id="B26-vaccines-08-00621"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Pawloski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weening</surname><given-names>K.</given-names></name><name name-style="western"><surname>DeBolt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kenyon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giambrone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kudish</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Pertactin-Negative Bordetella pertussis Strains: Evidence for a Possible Selective Advantage</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>60</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu788</pub-id><pub-id pub-id-type="pmid">25301209</pub-id></element-citation></ref><ref id="B27-vaccines-08-00621"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Octavia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maharjan</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Sintchenko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>R.</given-names></name></person-group><article-title>Insight into Evolution of Bordetella pertussis from Comparative Genomic Analysis: Evidence of Vaccine-Driven Selection</article-title><source>Mol. Biol. Evol.</source><year>2010</year><volume>28</volume><fpage>707</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1093/molbev/msq245</pub-id><pub-id pub-id-type="pmid">20833694</pub-id></element-citation></ref><ref id="B28-vaccines-08-00621"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safarchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Octavia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luu</surname><given-names>L.D.W.</given-names></name><name name-style="western"><surname>Tay</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Sintchenko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>H.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>R.</given-names></name></person-group><article-title>Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>6277</fpage><lpage>6281</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.064</pub-id><pub-id pub-id-type="pmid">26432908</pub-id></element-citation></ref><ref id="B29-vaccines-08-00621"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gothefors</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Storsaeter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Bordetella pertussis Respiratory Infection in Children Is Associated with Preferential Activation of Type 1 T Helper Cells</article-title><source>J. Infect. Dis.</source><year>1997</year><volume>175</volume><fpage>1246</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1086/593682</pub-id><pub-id pub-id-type="pmid">9129097</pub-id></element-citation></ref><ref id="B30-vaccines-08-00621"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahon</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.</given-names></name></person-group><article-title>Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes</article-title><source>J. Exp. Med.</source><year>1997</year><volume>186</volume><fpage>1843</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1084/jem.186.11.1843</pub-id><pub-id pub-id-type="pmid">9382883</pub-id><pub-id pub-id-type="pmcid">PMC2199147</pub-id></element-citation></ref><ref id="B31-vaccines-08-00621"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warfel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>T.J.</given-names></name></person-group><article-title>Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis</article-title><source>Clin. Vaccine Immunol.</source><year>2015</year><volume>23</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1128/CVI.00449-15</pub-id><pub-id pub-id-type="pmid">26561389</pub-id><pub-id pub-id-type="pmcid">PMC4711092</pub-id></element-citation></ref><ref id="B32-vaccines-08-00621"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Lung CD4 Tissue-Resident Memory T Cells Mediate Adaptive Immunity Induced by Previous Infection of Mice with Bordetella pertussis</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1602051</pub-id><pub-id pub-id-type="pmid">28533445</pub-id></element-citation></ref><ref id="B33-vaccines-08-00621"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borkner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>1763</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0080-x</pub-id><pub-id pub-id-type="pmid">30127384</pub-id></element-citation></ref><ref id="B34-vaccines-08-00621"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Borkner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aguil&#243;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thiriard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coutte</surname><given-names>L.</given-names></name><name name-style="western"><surname>Uranga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trottein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name><etal/></person-group><article-title>IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>1753</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0073-9</pub-id><pub-id pub-id-type="pmid">30115992</pub-id></element-citation></ref><ref id="B35-vaccines-08-00621"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Althouse</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Scarpino</surname><given-names>S.V.</given-names></name></person-group><article-title>Asymptomatic transmission and the resurgence of Bordetella pertussis</article-title><source>BMC Med.</source><year>2015</year><volume>13</volume><elocation-id>146</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-015-0382-8</pub-id><pub-id pub-id-type="pmid">26103968</pub-id><pub-id pub-id-type="pmcid">PMC4482312</pub-id></element-citation></ref><ref id="B36-vaccines-08-00621"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amirthalingam</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Hoek</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>E.</given-names></name></person-group><article-title>Investigating the pertussis resurgence in England and Wales, and options for future control</article-title><source>BMC Med.</source><year>2016</year><volume>14</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-016-0665-8</pub-id><pub-id pub-id-type="pmid">27580649</pub-id><pub-id pub-id-type="pmcid">PMC5007864</pub-id></element-citation></ref><ref id="B37-vaccines-08-00621"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burdin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Handy</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis vaccines</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2017</year><volume>9</volume><fpage>a029454</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a029454</pub-id><pub-id pub-id-type="pmid">28289064</pub-id><pub-id pub-id-type="pmcid">PMC5710106</pub-id></element-citation></ref><ref id="B38-vaccines-08-00621"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brummelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.G.H.</given-names></name><name name-style="western"><surname>van Els</surname><given-names>C.A.C.M.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Roads to the development of improved pertussis vaccines paved by immunology</article-title><source>Pathog. Dis.</source><year>2015</year><volume>73</volume><fpage>ftv067</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftv067</pub-id><pub-id pub-id-type="pmid">26347400</pub-id><pub-id pub-id-type="pmcid">PMC4626578</pub-id></element-citation></ref><ref id="B39-vaccines-08-00621"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coutte</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reveneau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Willery</surname><given-names>E.</given-names></name><name name-style="western"><surname>Quatannens</surname><given-names>B.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jacob-Dubuisson</surname><given-names>F.</given-names></name></person-group><article-title>Role of adhesin release for mucosal colonization by a bacterial pathogen</article-title><source>J. Exp. Med.</source><year>2003</year><volume>197</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1084/jem.20021153</pub-id><pub-id pub-id-type="pmid">12629063</pub-id><pub-id pub-id-type="pmcid">PMC2193847</pub-id></element-citation></ref><ref id="B40-vaccines-08-00621"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>A.</given-names></name></person-group><article-title>Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: Role of filamentous hemagglutinin and pertussis toxin</article-title><source>Microb. Pathog.</source><year>2002</year><volume>33</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1006/mpat.2002.0517</pub-id><pub-id pub-id-type="pmid">12220988</pub-id></element-citation></ref><ref id="B41-vaccines-08-00621"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahnsen</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Tobagus</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Napoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zosky</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sly</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Stumbles</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>P.G.</given-names></name></person-group><article-title>Accelerated Antigen Sampling and Transport by Airway Mucosal Dendritic Cells following Inhalation of a Bacterial Stimulus</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>5861</fpage><lpage>5867</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.9.5861</pub-id><pub-id pub-id-type="pmid">17056510</pub-id></element-citation></ref><ref id="B42-vaccines-08-00621"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbonetti</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Artamonova</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ayala</surname><given-names>V.I.</given-names></name></person-group><article-title>Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>1713</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1128/IAI.01578-06</pub-id><pub-id pub-id-type="pmid">17242062</pub-id><pub-id pub-id-type="pmcid">PMC1865687</pub-id></element-citation></ref><ref id="B43-vaccines-08-00621"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernard</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Tannahill</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.</given-names></name></person-group><article-title>A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against Bordetella pertussis</article-title><source>Mucosal Immunol.</source><year>2015</year><volume>8</volume><fpage>982</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1038/mi.2014.125</pub-id><pub-id pub-id-type="pmid">25515629</pub-id></element-citation></ref><ref id="B44-vaccines-08-00621"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raeven</surname><given-names>R.H.M.</given-names></name><name name-style="western"><surname>van der Maas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tilstra</surname><given-names>W.</given-names></name><name name-style="western"><surname>Uittenbogaard</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bindels</surname><given-names>T.H.E.</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>B.</given-names></name><name name-style="western"><surname>van der Ark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pennings</surname><given-names>J.L.A.</given-names></name><name name-style="western"><surname>van Riet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Immunoproteomic Profiling of Bordetella pertussis Outer Membrane Vesicle Vaccine Reveals Broad and Balanced Humoral Immunogenicity</article-title><source>J. Proteome Res.</source><year>2015</year><volume>14</volume><fpage>2929</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00258</pub-id><pub-id pub-id-type="pmid">25988566</pub-id></element-citation></ref><ref id="B45-vaccines-08-00621"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Hoogsteden</surname><given-names>H.C.</given-names></name></person-group><article-title>Lung dendritic cells and host immunity to infection</article-title><source>Eur. Respir. J.</source><year>2001</year><volume>18</volume><fpage>692</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">11716176</pub-id></element-citation></ref><ref id="B46-vaccines-08-00621"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>McCann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Keogh</surname><given-names>B.</given-names></name><name name-style="western"><surname>McNeela</surname><given-names>E.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;Gorman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jarnicki</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGuirk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Toll-Like Receptor 4-Mediated Innate IL-10 Activates Antigen-Specific Regulatory T Cells and Confers Resistance to Bordetella pertussis by Inhibiting Inflammatory Pathology</article-title><source>J. Immunol.</source><year>2003</year><volume>171</volume><fpage>3119</fpage><lpage>3127</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.6.3119</pub-id><pub-id pub-id-type="pmid">12960338</pub-id></element-citation></ref><ref id="B47-vaccines-08-00621"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunne</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>CD11c + CD8&#945; + Dendritic Cells Promote Protective Immunity to Respiratory Infection with Bordetella pertussis</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900169</pub-id><pub-id pub-id-type="pmid">19542451</pub-id></element-citation></ref><ref id="B48-vaccines-08-00621"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Raverdeau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>IL-17&#8211;Producing Innate and Pathogen-Specific Tissue Resident Memory &#947;&#948; T Cells Expand in the Lungs of Bordetella pertussis&#8211;Infected Mice</article-title><source>J. Immunol.</source><year>2016</year><volume>198</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601024</pub-id><pub-id pub-id-type="pmid">27864475</pub-id></element-citation></ref><ref id="B49-vaccines-08-00621"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreasen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carbonetti</surname><given-names>N.H.</given-names></name></person-group><article-title>Role of neutrophils in response to Bordetella pertussis infection in mice</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>1182</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1128/IAI.01150-08</pub-id><pub-id pub-id-type="pmid">19103765</pub-id><pub-id pub-id-type="pmcid">PMC2643619</pub-id></element-citation></ref><ref id="B50-vaccines-08-00621"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boehm</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Varney</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Sen-Kilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>DeRoos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bevere</surname><given-names>J.</given-names></name><name name-style="western"><surname>Epperly</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Characterizing the innate and adaptive responses of immunized mice to Bordetella pertussis infection using in vivo imaging and transcriptomic analysis</article-title><source>bioRxiv</source><year>2019</year><pub-id pub-id-type="doi">10.1101/674408</pub-id></element-citation></ref><ref id="B51-vaccines-08-00621"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>P.</given-names></name><name name-style="western"><surname>McGuirk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Todryk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells</article-title><source>Eur. J. Immunol.</source><year>2004</year><volume>34</volume><fpage>2579</fpage><lpage>2588</lpage><pub-id pub-id-type="doi">10.1002/eji.200425092</pub-id><pub-id pub-id-type="pmid">15307190</pub-id></element-citation></ref><ref id="B52-vaccines-08-00621"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leef</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Shahin</surname><given-names>R.D.</given-names></name></person-group><article-title>Role of gamma interferon in natural clearance of Bordetella pertussis infection</article-title><source>Infect. Immun.</source><year>1997</year><volume>65</volume><fpage>4904</fpage><lpage>4908</lpage><pub-id pub-id-type="doi">10.1128/IAI.65.12.4904-4908.1997</pub-id><pub-id pub-id-type="pmid">9393774</pub-id><pub-id pub-id-type="pmcid">PMC175707</pub-id></element-citation></ref><ref id="B53-vaccines-08-00621"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacMicking</surname><given-names>J.D.</given-names></name></person-group><article-title>Interferon-inducible effector mechanisms in cell-autonomous immunity</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>367</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/nri3210</pub-id><pub-id pub-id-type="pmid">22531325</pub-id><pub-id pub-id-type="pmcid">PMC4150610</pub-id></element-citation></ref><ref id="B54-vaccines-08-00621"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Immunity to the respiratory pathogen Bordetella pertussis</article-title><source>Mucosal Immunol.</source><year>2012</year><volume>5</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.54</pub-id><pub-id pub-id-type="pmid">22718262</pub-id></element-citation></ref><ref id="B55-vaccines-08-00621"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Redhead</surname><given-names>K.</given-names></name></person-group><article-title>Cell-mediated immunity to Bordetella pertussis: Role of Th1 cells in bacterial clearance in a murine respiratory infection model</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1128/IAI.61.2.399-410.1993</pub-id><pub-id pub-id-type="pmid">8423070</pub-id><pub-id pub-id-type="pmcid">PMC302743</pub-id></element-citation></ref><ref id="B56-vaccines-08-00621"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warfel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>T.J.</given-names></name></person-group><article-title>Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates</article-title><source>Mucosal Immunol.</source><year>2013</year><volume>6</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.117</pub-id><pub-id pub-id-type="pmid">23187316</pub-id></element-citation></ref><ref id="B57-vaccines-08-00621"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinuesa</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Linterman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>I.C.M.</given-names></name></person-group><article-title>Follicular Helper T Cells</article-title><source>Annu. Rev. Immunol.</source><year>2016</year><volume>34</volume><fpage>335</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-041015-055605</pub-id><pub-id pub-id-type="pmid">26907215</pub-id></element-citation></ref><ref id="B58-vaccines-08-00621"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Macaubas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monger</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Sly</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>P.G.</given-names></name></person-group><article-title>Antigen-Specific Responses to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Human Infants Are Initially Th2 Polarized</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>3873</fpage><lpage>3877</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.7.3873-3877.2000</pub-id><pub-id pub-id-type="pmid">10858197</pub-id><pub-id pub-id-type="pmcid">PMC101661</pub-id></element-citation></ref><ref id="B59-vaccines-08-00621"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bancroft</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>M.B.C.</given-names></name><name name-style="western"><surname>da Silva Antunes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lindestam Arlehamn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood</article-title><source>Cell. Immunol.</source><year>2016</year><volume>304&#8211;305</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2016.05.002</pub-id><pub-id pub-id-type="pmcid">PMC4899275</pub-id><pub-id pub-id-type="pmid">27212461</pub-id></element-citation></ref><ref id="B60-vaccines-08-00621"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salmaso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mastrantonio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giuliano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tozzi</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Anemona</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciofi degli Atti</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Giammanco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blackwelder</surname><given-names>W.C.</given-names></name><etal/></person-group><article-title>A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis</article-title><source>N. Engl. J. Med.</source><year>1996</year><volume>334</volume><fpage>341</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1056/NEJM199602083340601</pub-id><pub-id pub-id-type="pmid">8538704</pub-id></element-citation></ref><ref id="B61-vaccines-08-00621"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sealey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Belcher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>A.</given-names></name></person-group><article-title>Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence</article-title><source>Infect. Genet. Evol.</source><year>2016</year><volume>40</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2016.02.032</pub-id><pub-id pub-id-type="pmid">26932577</pub-id></element-citation></ref><ref id="B62-vaccines-08-00621"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambhir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Cauchemez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tartof</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>N.M.</given-names></name></person-group><article-title>A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States</article-title><source>PLoS Comput. Biol.</source><year>2015</year><volume>11</volume><elocation-id>e1004138</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004138</pub-id><pub-id pub-id-type="pmid">25906150</pub-id><pub-id pub-id-type="pmcid">PMC4408109</pub-id></element-citation></ref><ref id="B63-vaccines-08-00621"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherry</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Heininger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Storsaeter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ljungman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hallander</surname><given-names>H.O.</given-names></name></person-group><article-title>Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>741</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1128/CVI.00469-09</pub-id><pub-id pub-id-type="pmid">20335431</pub-id><pub-id pub-id-type="pmcid">PMC2863370</pub-id></element-citation></ref><ref id="B64-vaccines-08-00621"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrikx</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Schure</surname><given-names>R.-M.</given-names></name><name name-style="western"><surname>&#214;zt&#252;rk</surname><given-names>K.</given-names></name><name name-style="western"><surname>de Rond</surname><given-names>L.G.H.</given-names></name><name name-style="western"><surname>de Greeff</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>E.A.M.</given-names></name><name name-style="western"><surname>Berbers</surname><given-names>G.A.M.</given-names></name><name name-style="western"><surname>Buisman</surname><given-names>A.-M.</given-names></name></person-group><article-title>Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6874</fpage><lpage>6880</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.055</pub-id><pub-id pub-id-type="pmid">21803088</pub-id></element-citation></ref><ref id="B65-vaccines-08-00621"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mahon</surname><given-names>B.P.</given-names></name></person-group><article-title>A Murine Model in Which Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals Complementary Roles for Humoral and Cell-Mediated Immunity in Protection againstBordetella pertussis</article-title><source>Infect. Immun.</source><year>1998</year><volume>66</volume><fpage>594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1128/IAI.66.2.594-602.1998</pub-id><pub-id pub-id-type="pmid">9453614</pub-id><pub-id pub-id-type="pmcid">PMC107945</pub-id></element-citation></ref><ref id="B66-vaccines-08-00621"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>B.W.P.</given-names></name><name name-style="western"><surname>Lebman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Hiraki</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Shrader</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cherwinski</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Savelkoul</surname><given-names>H.F.J.</given-names></name><name name-style="western"><surname>Finkelman</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Bond</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation</article-title><source>Immunol. Rev.</source><year>1988</year><volume>102</volume><fpage>5</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.1988.tb00739.x</pub-id><pub-id pub-id-type="pmid">2966762</pub-id></element-citation></ref><ref id="B67-vaccines-08-00621"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bossie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vitetta</surname><given-names>E.S.</given-names></name></person-group><article-title>IFN-&#947; enhances secretion of IgG2a from IgG2a-committed LPS-stimulated murine B cells: Implications for the role of IFN-&#947; in class switching</article-title><source>Cell. Immunol.</source><year>1991</year><volume>135</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/0008-8749(91)90257-C</pub-id><pub-id pub-id-type="pmid">1902147</pub-id></element-citation></ref><ref id="B68-vaccines-08-00621"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Goldschmidt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Salter</surname><given-names>H.</given-names></name></person-group><article-title>Possible allelic structure of IgG2a and IgG2c in mice</article-title><source>Mol. Immunol.</source><year>2012</year><volume>50</volume><fpage>169</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2011.11.006</pub-id><pub-id pub-id-type="pmid">22177661</pub-id></element-citation></ref><ref id="B69-vaccines-08-00621"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Severinson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heusser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>S.G.O.</given-names></name><name name-style="western"><surname>M&#246;ller</surname><given-names>G.</given-names></name><name name-style="western"><surname>Persson</surname><given-names>U.</given-names></name></person-group><article-title>Regulation of IgG1 and IgE Synthesis by Interleukin 4 in Mouse B Cells</article-title><source>Scand. J. Immunol.</source><year>1989</year><volume>30</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.1989.tb01221.x</pub-id><pub-id pub-id-type="pmid">2789429</pub-id></element-citation></ref><ref id="B70-vaccines-08-00621"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellwig</surname><given-names>S.M.M.</given-names></name><name name-style="western"><surname>van Oirschot</surname><given-names>H.F.L.M.</given-names></name><name name-style="western"><surname>Hazenbos</surname><given-names>W.L.W.</given-names></name><name name-style="western"><surname>van Spriel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>van de Winkel</surname><given-names>J.G.J.</given-names></name></person-group><article-title>Targeting to Fc&#947; Receptors, But Not CR3 (CD11b/CD18), Increases Clearance of Bordetella pertussis</article-title><source>J. Infect. Dis.</source><year>2001</year><volume>183</volume><fpage>871</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1086/319266</pub-id><pub-id pub-id-type="pmid">11237803</pub-id></element-citation></ref><ref id="B71-vaccines-08-00621"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidarsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rispens</surname><given-names>T.</given-names></name></person-group><article-title>IgG Subclasses and Allotypes: From Structure to Effector Functions</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>520</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00520</pub-id><pub-id pub-id-type="pmid">25368619</pub-id><pub-id pub-id-type="pmcid">PMC4202688</pub-id></element-citation></ref><ref id="B72-vaccines-08-00621"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Apostolovic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jahnmatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ols</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tecleab</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Hage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Solovay</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans</article-title><source>J. Clin. Investig.</source><year>2020</year><volume>130</volume><fpage>2332</fpage><lpage>2346</lpage><pub-id pub-id-type="doi">10.1172/JCI135020</pub-id><pub-id pub-id-type="pmid">31945015</pub-id><pub-id pub-id-type="pmcid">PMC7190984</pub-id></element-citation></ref><ref id="B73-vaccines-08-00621"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuomanen</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Zapiain</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Galvan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hewlett</surname><given-names>E.L.</given-names></name></person-group><article-title>Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells</article-title><source>J. Clin. Microbiol.</source><year>1984</year><volume>20</volume><fpage>167</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1128/JCM.20.2.167-170.1984</pub-id><pub-id pub-id-type="pmid">6092416</pub-id><pub-id pub-id-type="pmcid">PMC271278</pub-id></element-citation></ref><ref id="B74-vaccines-08-00621"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellwig</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>van Spriel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Schellekens</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>van de Winkel</surname><given-names>J.G.</given-names></name></person-group><article-title>Immunoglobulin A-mediated protection against Bordetella pertussis infection</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>4846</fpage><lpage>4850</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.8.4846-4850.2001</pub-id><pub-id pub-id-type="pmid">11447159</pub-id><pub-id pub-id-type="pmcid">PMC98573</pub-id></element-citation></ref><ref id="B75-vaccines-08-00621"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosenkrands</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name></person-group><article-title>Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses</article-title><source>Mucosal Immunol.</source><year>2017</year><volume>10</volume><fpage>260</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.28</pub-id><pub-id pub-id-type="pmid">27049058</pub-id></element-citation></ref><ref id="B76-vaccines-08-00621"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaffar</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ferrini</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Herritt</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>K.</given-names></name></person-group><article-title>Cutting Edge: Lung Mucosal Th17-Mediated Responses Induce Polymeric Ig Receptor Expression by the Airway Epithelium and Elevate Secretory IgA Levels</article-title><source>J. Immunol.</source><year>2009</year><volume>182</volume><fpage>4507</fpage><lpage>4511</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900237</pub-id><pub-id pub-id-type="pmid">19342622</pub-id><pub-id pub-id-type="pmcid">PMC2740792</pub-id></element-citation></ref><ref id="B77-vaccines-08-00621"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redhead</surname><given-names>K.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.</given-names></name></person-group><article-title>Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>3190</fpage><lpage>3198</lpage><pub-id pub-id-type="doi">10.1128/IAI.61.8.3190-3198.1993</pub-id><pub-id pub-id-type="pmid">8335349</pub-id><pub-id pub-id-type="pmcid">PMC280987</pub-id></element-citation></ref><ref id="B78-vaccines-08-00621"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagamatsu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuwae</surname><given-names>A.</given-names></name><name name-style="western"><surname>Konaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mimuro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koyasu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>A.</given-names></name></person-group><article-title>Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN</article-title><source>J. Exp. Med.</source><year>2009</year><volume>206</volume><fpage>3073</fpage><lpage>3088</lpage><pub-id pub-id-type="doi">10.1084/jem.20090494</pub-id><pub-id pub-id-type="pmid">20008527</pub-id><pub-id pub-id-type="pmcid">PMC2806459</pub-id></element-citation></ref><ref id="B79-vaccines-08-00621"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosser</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Interleukin-10: New perspectives on an old cytokine</article-title><source>Immunol. Rev.</source><year>2008</year><volume>226</volume><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00706.x</pub-id><pub-id pub-id-type="pmid">19161426</pub-id><pub-id pub-id-type="pmcid">PMC2724982</pub-id></element-citation></ref><ref id="B80-vaccines-08-00621"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saraiva</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Garra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Garra</surname><given-names>A.</given-names></name></person-group><article-title>The regulation of IL-10 production by immune cells</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>170</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/nri2711</pub-id><pub-id pub-id-type="pmid">20154735</pub-id></element-citation></ref><ref id="B81-vaccines-08-00621"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuirk</surname><given-names>P.</given-names></name><name name-style="western"><surname>McCann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: A novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis</article-title><source>J. Exp. Med.</source><year>2002</year><volume>195</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1084/jem.20011288</pub-id><pub-id pub-id-type="pmid">11805149</pub-id><pub-id pub-id-type="pmcid">PMC2193600</pub-id></element-citation></ref><ref id="B82-vaccines-08-00621"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirix</surname><given-names>V.</given-names></name><name name-style="western"><surname>Verscheure</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Schutter</surname><given-names>I.</given-names></name><name name-style="western"><surname>Goetghebuer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mascart</surname><given-names>F.</given-names></name></person-group><article-title>Both CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes participate in the IFN-&#947; response to filamentous hemagglutinin from Bordetella pertussis in infants, children, and adults</article-title><source>Clin. Dev. Immunol.</source><year>2012</year><volume>2012</volume><fpage>795958</fpage><pub-id pub-id-type="doi">10.1155/2012/795958</pub-id><pub-id pub-id-type="pmid">22550536</pub-id><pub-id pub-id-type="pmcid">PMC3329133</pub-id></element-citation></ref><ref id="B83-vaccines-08-00621"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raeven</surname><given-names>R.H.M.</given-names></name><name name-style="western"><surname>Brummelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pennings</surname><given-names>J.L.A.</given-names></name><name name-style="western"><surname>Nijst</surname><given-names>O.E.M.</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blok</surname><given-names>L.E.R.</given-names></name><name name-style="western"><surname>Helm</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Riet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>van Els</surname><given-names>C.A.C.M.</given-names></name><etal/></person-group><article-title>Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e104548</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104548</pub-id><pub-id pub-id-type="pmid">25137043</pub-id><pub-id pub-id-type="pmcid">PMC4138111</pub-id></element-citation></ref><ref id="B84-vaccines-08-00621"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argondizo-Correia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A.K.S.</given-names></name><name name-style="western"><surname>de Brito</surname><given-names>C.A.</given-names></name></person-group><article-title>Neonatal Immunity to <italic toggle="yes">Bordetella pertussis</italic> Infection and Current Prevention Strategies</article-title><source>J. Immunol. Res.</source><year>2019</year><volume>2019</volume><fpage>7134168</fpage><pub-id pub-id-type="doi">10.1155/2019/7134168</pub-id><pub-id pub-id-type="pmid">30882004</pub-id><pub-id pub-id-type="pmcid">PMC6387735</pub-id></element-citation></ref><ref id="B85-vaccines-08-00621"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Klimecki</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Vercelli</surname><given-names>D.</given-names></name></person-group><article-title>The human IL-13 locus in neonatal CD4+ T cells is refractory to the acquisition of a repressive chromatin architecture</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>700</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1074/jbc.M609501200</pub-id><pub-id pub-id-type="pmid">17090525</pub-id></element-citation></ref><ref id="B86-vaccines-08-00621"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hebel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weinert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuropka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Knolle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kosak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jorch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>E.</given-names></name><name name-style="western"><surname>Braun-Dullaeus</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Brunner-Weinzierl</surname><given-names>M.C.</given-names></name></person-group><article-title>CD4+ T cells from human neonates and infants are poised spontaneously to run a nonclassical IL-4 program</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>5160</fpage><lpage>5170</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302539</pub-id><pub-id pub-id-type="pmid">24778440</pub-id></element-citation></ref><ref id="B87-vaccines-08-00621"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adkins</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yoshimoto</surname><given-names>M.</given-names></name></person-group><article-title>Epigenetic Regulation of the Th2 Locus in Fetal and Neonatal T Cells</article-title><source>Adv. Neuroimmune Biol.</source><year>2014</year><volume>5</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3233/NIB-140078</pub-id></element-citation></ref><ref id="B88-vaccines-08-00621"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascart</surname><given-names>F.</given-names></name><name name-style="western"><surname>Verscheure</surname><given-names>V.</given-names></name><name name-style="western"><surname>Malfroot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hainaut</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pi&#233;rard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Temerman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peltier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Bordetella pertussis Infection in 2-Month-Old Infants Promotes Type 1 T Cell Responses</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>1504</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.3.1504</pub-id><pub-id pub-id-type="pmid">12538714</pub-id></element-citation></ref><ref id="B89-vaccines-08-00621"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langrish</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Basham</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sedgwick</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>McClanahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kastelein</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Cua</surname><given-names>D.J.</given-names></name></person-group><article-title>IL-23 drives a pathogenic T cell population that induces autoimmune inflammation</article-title><source>J. Exp. Med.</source><year>2005</year><volume>201</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1084/jem.20041257</pub-id><pub-id pub-id-type="pmid">15657292</pub-id><pub-id pub-id-type="pmcid">PMC2212798</pub-id></element-citation></ref><ref id="B90-vaccines-08-00621"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Induction, function and regulation of IL-17-producing T cells</article-title><source>Eur. J. Immunol.</source><year>2008</year><volume>38</volume><fpage>2636</fpage><lpage>2649</lpage><pub-id pub-id-type="doi">10.1002/eji.200838535</pub-id><pub-id pub-id-type="pmid">18958872</pub-id></element-citation></ref><ref id="B91-vaccines-08-00621"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolls</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Khader</surname><given-names>S.A.</given-names></name></person-group><article-title>The role of Th17 cytokines in primary mucosal immunity</article-title><source>Cytokine Growth Factor Rev.</source><year>2010</year><volume>21</volume><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2010.11.002</pub-id><pub-id pub-id-type="pmid">21095154</pub-id><pub-id pub-id-type="pmcid">PMC3004678</pub-id></element-citation></ref><ref id="B92-vaccines-08-00621"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Papin</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Lecher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Thalen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Solovay</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mielcarek</surname><given-names>N.</given-names></name></person-group><article-title>Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons against Bordetella pertussis Disease and Infection</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix254</pub-id><pub-id pub-id-type="pmid">28535276</pub-id><pub-id pub-id-type="pmcid">PMC5853371</pub-id></element-citation></ref><ref id="B93-vaccines-08-00621"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jarnicki</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>TLR4 Mediates Vaccine-Induced Protective Cellular Immunity to Bordetella pertussis: Role of IL-17-Producing T Cells</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>7980</fpage><lpage>7989</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.11.7980</pub-id><pub-id pub-id-type="pmid">17114471</pub-id></element-citation></ref><ref id="B94-vaccines-08-00621"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Pospisilova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Masin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meaney</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tschopp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sebo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Inflammasome Activation by Adenylate Cyclase Toxin Directs Th17 Responses and Protection against Bordetella pertussis</article-title><source>J. Immunol.</source><year>2010</year><volume>185</volume><fpage>1711</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000105</pub-id><pub-id pub-id-type="pmid">20610650</pub-id></element-citation></ref><ref id="B95-vaccines-08-00621"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva Antunes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Babor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Seumois</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petro</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Vijayanand</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>3853</fpage><lpage>3865</lpage><pub-id pub-id-type="doi">10.1172/JCI121309</pub-id><pub-id pub-id-type="pmid">29920186</pub-id><pub-id pub-id-type="pmcid">PMC6118631</pub-id></element-citation></ref><ref id="B96-vaccines-08-00621"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hendrikx</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>E.A.M.</given-names></name><name name-style="western"><surname>Berbers</surname><given-names>G.A.M.</given-names></name><name name-style="western"><surname>Buisman</surname><given-names>A.-M.</given-names></name></person-group><article-title>Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00051</pub-id><pub-id pub-id-type="pmid">29416544</pub-id><pub-id pub-id-type="pmcid">PMC5787539</pub-id></element-citation></ref><ref id="B97-vaccines-08-00621"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallusto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lenig</surname><given-names>D.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><article-title>Two subsets of memory T lymphocytes with distinct homing potentials and effector functions</article-title><source>Nature</source><year>1999</year><volume>401</volume><fpage>708</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/44385</pub-id><pub-id pub-id-type="pmid">10537110</pub-id></element-citation></ref><ref id="B98-vaccines-08-00621"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name></person-group><article-title>Tissue-resident memory T cells: Local specialists in immune defence</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/nri.2015.3</pub-id><pub-id pub-id-type="pmid">26688350</pub-id></element-citation></ref><ref id="B99-vaccines-08-00621"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebhardt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wakim</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Eidsmo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reading</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>F.R.</given-names></name></person-group><article-title>Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus</article-title><source>Nat. Immunol.</source><year>2009</year><volume>10</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/ni.1718</pub-id><pub-id pub-id-type="pmid">19305395</pub-id></element-citation></ref><ref id="B100-vaccines-08-00621"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name><name name-style="western"><surname>Choo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vezys</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Duraiswamy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Akondy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Dynamic T cell migration program provides resident memory within intestinal epithelium</article-title><source>J. Exp. Med.</source><year>2010</year><volume>207</volume><fpage>553</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1084/jem.20090858</pub-id><pub-id pub-id-type="pmid">20156972</pub-id><pub-id pub-id-type="pmcid">PMC2839151</pub-id></element-citation></ref><ref id="B101-vaccines-08-00621"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Miron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Granot</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guyer</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Senda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites</article-title><source>Cell Rep.</source><year>2017</year><volume>20</volume><fpage>2921</fpage><lpage>2934</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.08.078</pub-id><pub-id pub-id-type="pmid">28930685</pub-id><pub-id pub-id-type="pmcid">PMC5646692</pub-id></element-citation></ref><ref id="B102-vaccines-08-00621"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Macleod</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tebartz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bedoui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Gebhardt</surname><given-names>T.</given-names></name></person-group><article-title>Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>2059</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402256</pub-id><pub-id pub-id-type="pmid">25624457</pub-id></element-citation></ref><ref id="B103-vaccines-08-00621"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teijaro</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Lefran&#231;ois</surname><given-names>L.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>D.L.</given-names></name></person-group><article-title>Cutting Edge: Tissue-Retentive Lung Memory CD4 T Cells Mediate Optimal Protection to Respiratory Virus Infection</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>5510</fpage><lpage>5514</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102243</pub-id><pub-id pub-id-type="pmid">22058417</pub-id><pub-id pub-id-type="pmcid">PMC3221837</pub-id></element-citation></ref><ref id="B104-vaccines-08-00621"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>McSorley</surname><given-names>S.J.</given-names></name></person-group><article-title>Divergent behavior of mucosal memory T cells</article-title><source>Mucosal Immunol.</source><year>2015</year><volume>8</volume><fpage>731</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/mi.2015.52</pub-id><pub-id pub-id-type="pmid">26059005</pub-id><pub-id pub-id-type="pmcid">PMC4930071</pub-id></element-citation></ref><ref id="B105-vaccines-08-00621"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenkel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Beura</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Pauken</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Vezys</surname><given-names>V.</given-names></name><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name></person-group><article-title>Resident memory CD8 T cells trigger protective innate and adaptive immune responses</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1126/science.1254536</pub-id><pub-id pub-id-type="pmid">25170049</pub-id><pub-id pub-id-type="pmcid">PMC4449618</pub-id></element-citation></ref><ref id="B106-vaccines-08-00621"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenkel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Vezys</surname><given-names>V.</given-names></name><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name></person-group><article-title>Sensing and alarm function of resident memory CD8<sup>+</sup> T cells</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1038/ni.2568</pub-id><pub-id pub-id-type="pmid">23542740</pub-id><pub-id pub-id-type="pmcid">PMC3631432</pub-id></element-citation></ref><ref id="B107-vaccines-08-00621"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmkvist</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roepstorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uronen-Hansson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sand&#233;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patschan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Grip</surname><given-names>O.</given-names></name><name name-style="western"><surname>Marsal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schmidtchen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornum</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A major population of mucosal memory CD4+ T cells, coexpressing IL-18R&#945; and DR3, display innate lymphocyte functionality</article-title><source>Mucosal Immunol.</source><year>2015</year><volume>8</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/mi.2014.87</pub-id><pub-id pub-id-type="pmid">25269704</pub-id><pub-id pub-id-type="pmcid">PMC4424383</pub-id></element-citation></ref><ref id="B108-vaccines-08-00621"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lefran&#231;ois</surname><given-names>L.</given-names></name></person-group><article-title>Direct Analysis of the Dynamics of the Intestinal Mucosa CD8 T Cell Response to Systemic Virus Infection</article-title><source>J. Immunol.</source><year>2001</year><volume>166</volume><fpage>2348</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.4.2348</pub-id><pub-id pub-id-type="pmid">11160292</pub-id></element-citation></ref><ref id="B109-vaccines-08-00621"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bonneau</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kinchington</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>R.L.</given-names></name></person-group><article-title>Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia</article-title><source>Immunity</source><year>2003</year><volume>18</volume><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(03)00112-2</pub-id><pub-id pub-id-type="pmid">12753737</pub-id><pub-id pub-id-type="pmcid">PMC2871305</pub-id></element-citation></ref><ref id="B110-vaccines-08-00621"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iijima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1126/science.1257530</pub-id><pub-id pub-id-type="pmid">25170048</pub-id><pub-id pub-id-type="pmcid">PMC4254703</pub-id></element-citation></ref><ref id="B111-vaccines-08-00621"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinnear</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>L.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Caproni</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tregoning</surname><given-names>J.S.</given-names></name></person-group><article-title>Airway T cells protect against RSV infection in the absence of antibody</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1038/mi.2017.46</pub-id><pub-id pub-id-type="pmid">28537249</pub-id></element-citation></ref><ref id="B112-vaccines-08-00621"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mangalam</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Airway Memory CD4<sup>+</sup> T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses</article-title><source>Immunity</source><year>2016</year><volume>44</volume><fpage>1379</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.006</pub-id><pub-id pub-id-type="pmid">27287409</pub-id><pub-id pub-id-type="pmcid">PMC4917442</pub-id></element-citation></ref><ref id="B113-vaccines-08-00621"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zens</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>D.L.</given-names></name></person-group><article-title>Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><fpage>e85832</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.85832</pub-id><pub-id pub-id-type="pmid">27468427</pub-id><pub-id pub-id-type="pmcid">PMC4959801</pub-id></element-citation></ref><ref id="B114-vaccines-08-00621"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMaster</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kohlmeier</surname><given-names>J.E.</given-names></name></person-group><article-title>Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection against Respiratory Virus Challenge through Rapid IFN-&#947; Production</article-title><source>J. Immunol.</source><year>2015</year><volume>195</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402975</pub-id><pub-id pub-id-type="pmid">26026054</pub-id><pub-id pub-id-type="pmcid">PMC4475417</pub-id></element-citation></ref><ref id="B115-vaccines-08-00621"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paik</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>D.L.</given-names></name></person-group><article-title>Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity</article-title><source>J. Exp. Med.</source><year>2020</year><volume>218</volume><fpage>e20200218</fpage><pub-id pub-id-type="doi">10.1084/jem.20200218</pub-id><pub-id pub-id-type="pmcid">PMC7534905</pub-id><pub-id pub-id-type="pmid">33005934</pub-id></element-citation></ref><ref id="B116-vaccines-08-00621"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Hilliard</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lipsitz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Malley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dooms</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Quinton</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>220</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/mi.2017.43</pub-id><pub-id pub-id-type="pmid">28513594</pub-id><pub-id pub-id-type="pmcid">PMC5693795</pub-id></element-citation></ref><ref id="B117-vaccines-08-00621"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monk</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Pizzolla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Stinear</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Westall</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Wakim</surname><given-names>L.M.</given-names></name></person-group><article-title>Bystander Activation of Pulmonary Trm Cells Attenuates the Severity of Bacterial Pneumonia by Enhancing Neutrophil Recruitment</article-title><source>Cell Rep.</source><year>2019</year><volume>29</volume><fpage>4236</fpage><lpage>4244.e3</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.11.103</pub-id><pub-id pub-id-type="pmid">31875535</pub-id></element-citation></ref><ref id="B118-vaccines-08-00621"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodworth</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Moguche</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Plumlee</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Urdahl</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name></person-group><article-title>Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung</article-title><source>Mucosal Immunol.</source><year>2017</year><volume>10</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.70</pub-id><pub-id pub-id-type="pmid">27554293</pub-id><pub-id pub-id-type="pmcid">PMC5325828</pub-id></element-citation></ref><ref id="B119-vaccines-08-00621"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Zak</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Malouli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gilbride</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>130</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/nm.4473</pub-id><pub-id pub-id-type="pmid">29334373</pub-id><pub-id pub-id-type="pmcid">PMC5909823</pub-id></element-citation></ref><ref id="B120-vaccines-08-00621"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Kaveh</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Garcia-Pelayo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Stylianou</surname><given-names>E.</given-names></name><name name-style="western"><surname>McShane</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hogarth</surname><given-names>P.J.</given-names></name></person-group><article-title>Induction and maintenance of a phenotypically heterogeneous lung tissue-resident CD4+ T cell population following BCG immunisation</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5625</fpage><lpage>5635</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.07.035</pub-id><pub-id pub-id-type="pmid">30097220</pub-id><pub-id pub-id-type="pmcid">PMC6143486</pub-id></element-citation></ref><ref id="B121-vaccines-08-00621"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mielcarek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Raze</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bertout</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rouanet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Creusy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Engle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name></person-group><article-title>Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough</article-title><source>PLoS Pathog.</source><year>2006</year><volume>2</volume><elocation-id>e65</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0020065</pub-id><pub-id pub-id-type="pmid">16839199</pub-id><pub-id pub-id-type="pmcid">PMC1487175</pub-id></element-citation></ref><ref id="B122-vaccines-08-00621"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorstensson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trollfors</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al-Tawil</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jahnmatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergstrom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ljungman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wehlin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Broekhoven</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e83449</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0083449</pub-id><pub-id pub-id-type="pmid">24421886</pub-id><pub-id pub-id-type="pmcid">PMC3885431</pub-id></element-citation></ref><ref id="B123-vaccines-08-00621"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feunou</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Kammoun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Mielcarek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name></person-group><article-title>Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7047</fpage><lpage>7053</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.017</pub-id><pub-id pub-id-type="pmid">20708998</pub-id></element-citation></ref><ref id="B124-vaccines-08-00621"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feunou Feunou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bertout</surname><given-names>J.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name></person-group><article-title>T- and B-Cell-Mediated Protection Induced by Novel, Live Attenuated Pertussis Vaccine in Mice. Cross Protection against Parapertussis</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e10178</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0010178</pub-id><pub-id pub-id-type="pmid">20419113</pub-id><pub-id pub-id-type="pmcid">PMC2855369</pub-id></element-citation></ref><ref id="B125-vaccines-08-00621"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skerry</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mahon</surname><given-names>B.P.</given-names></name></person-group><article-title>A Live, Attenuated Bordetella pertussis Vaccine Provides Long-Term Protection against Virulent Challenge in a Murine Model</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1128/CVI.00371-10</pub-id><pub-id pub-id-type="pmid">21147936</pub-id><pub-id pub-id-type="pmcid">PMC3067348</pub-id></element-citation></ref><ref id="B126-vaccines-08-00621"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Mielcarek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lecher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sirard</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name></person-group><article-title>Early Protection against Pertussis Induced by Live Attenuated Bordetella pertussis BPZE1 Depends on TLR4</article-title><source>J. Immunol.</source><year>2019</year><volume>203</volume><fpage>3293</fpage><lpage>3300</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1901102</pub-id><pub-id pub-id-type="pmid">31732529</pub-id></element-citation></ref><ref id="B127-vaccines-08-00621"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedele</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Debrie</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ausiello</surname><given-names>C.M.</given-names></name></person-group><article-title>Attenuated Bordetella pertussis Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced Migration and Drives a Th1/Th17 Response</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>5388</fpage><lpage>5396</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003765</pub-id><pub-id pub-id-type="pmid">21430219</pub-id></element-citation></ref><ref id="B128-vaccines-08-00621"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwechheimer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>M.J.</given-names></name></person-group><article-title>Outer-membrane vesicles from Gram-negative bacteria: Biogenesis and functions</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>605</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3525</pub-id><pub-id pub-id-type="pmid">26373371</pub-id><pub-id pub-id-type="pmcid">PMC5308417</pub-id></element-citation></ref><ref id="B129-vaccines-08-00621"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raeven</surname><given-names>R.H.M.</given-names></name><name name-style="western"><surname>Brummelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pennings</surname><given-names>J.L.A.</given-names></name><name name-style="western"><surname>van der Maas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tilstra</surname><given-names>W.</given-names></name><name name-style="western"><surname>Helm</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Riet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>van Els</surname><given-names>C.A.C.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.G.H.</given-names></name><etal/></person-group><article-title>Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>38240</fpage><pub-id pub-id-type="doi">10.1038/srep38240</pub-id><pub-id pub-id-type="pmid">27905535</pub-id><pub-id pub-id-type="pmcid">PMC5131296</pub-id></element-citation></ref><ref id="B130-vaccines-08-00621"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bottero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Fingermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Graieb</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hozbor</surname><given-names>D.</given-names></name></person-group><article-title>Outer membrane vesicles as acellular vaccine against pertussis</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>4639</fpage><lpage>4646</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.004</pub-id><pub-id pub-id-type="pmid">18640169</pub-id></element-citation></ref><ref id="B131-vaccines-08-00621"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zurita</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Carriquiriborde</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bartel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name><name name-style="western"><surname>Hozbor</surname><given-names>D.</given-names></name></person-group><article-title>A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis, Including Pertactin Deficient Strains</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>125</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00125</pub-id><pub-id pub-id-type="pmid">31106160</pub-id><pub-id pub-id-type="pmcid">PMC6498398</pub-id></element-citation></ref><ref id="B132-vaccines-08-00621"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bottero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Bartel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carriquiriborde</surname><given-names>F.</given-names></name><name name-style="western"><surname>Errea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Castuma</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Characterization of the immune response induced by pertussis OMVs-based vaccine</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>3303</fpage><lpage>3309</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.079</pub-id><pub-id pub-id-type="pmid">27151884</pub-id></element-citation></ref><ref id="B133-vaccines-08-00621"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaillard</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Bottero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Errea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ormaz&#225;bal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Castuma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bartel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.12.048</pub-id><pub-id pub-id-type="pmid">24397896</pub-id></element-citation></ref><ref id="B134-vaccines-08-00621"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asensio</surname><given-names>C.J.A.</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bottero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Ley</surname><given-names>P.</given-names></name><name name-style="western"><surname>van der Ark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hozbor</surname><given-names>D.</given-names></name></person-group><article-title>Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>1649</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.068</pub-id><pub-id pub-id-type="pmid">21211579</pub-id></element-citation></ref><ref id="B135-vaccines-08-00621"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Loscher</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>IL-1&#946;-dependent neurological effects of the whole cell pertussis vaccine: A role for IL-1-associated signalling components in vaccine reactogenicity</article-title><source>J. Neuroimmunol.</source><year>2003</year><volume>136</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(02)00468-X</pub-id><pub-id pub-id-type="pmid">12620640</pub-id></element-citation></ref><ref id="B136-vaccines-08-00621"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raeven</surname><given-names>R.H.M.</given-names></name><name name-style="western"><surname>Brummelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pennings</surname><given-names>J.L.A.</given-names></name><name name-style="western"><surname>van der Maas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Helm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tilstra</surname><given-names>W.</given-names></name><name name-style="western"><surname>van der Ark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sloots</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Ley</surname><given-names>P.</given-names></name><name name-style="western"><surname>van Eden</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>979</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/mi.2017.81</pub-id><pub-id pub-id-type="pmid">28930286</pub-id></element-citation></ref><ref id="B137-vaccines-08-00621"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raeven</surname><given-names>R.H.M.</given-names></name><name name-style="western"><surname>Rockx-Brouwer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kanojia</surname><given-names>G.</given-names></name><name name-style="western"><surname>van der Maas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bindels</surname><given-names>T.H.E.</given-names></name><name name-style="western"><surname>ten Have</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Riet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Metz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.F.A.</given-names></name></person-group><article-title>Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>7396</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-63998-2</pub-id><pub-id pub-id-type="pmid">32355188</pub-id><pub-id pub-id-type="pmcid">PMC7192948</pub-id></element-citation></ref><ref id="B138-vaccines-08-00621"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pawloski</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Queenan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cassiday</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Burgos-Rivera</surname><given-names>B.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1128/CVI.00717-13</pub-id><pub-id pub-id-type="pmid">24256623</pub-id><pub-id pub-id-type="pmcid">PMC3910938</pub-id></element-citation></ref><ref id="B139-vaccines-08-00621"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooi</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>van Loo</surname><given-names>I.H.M.</given-names></name><name name-style="western"><surname>van Gent</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Heuvelman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>de Greeff</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Diavatopoulos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teunis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nagelkerke</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Bordetella pertussis strains with increased toxin production associated with pertussis resurgence</article-title><source>Emerg. Infect. Dis.</source><year>2009</year><volume>15</volume><fpage>1206</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.3201/eid1508.081511</pub-id><pub-id pub-id-type="pmid">19751581</pub-id><pub-id pub-id-type="pmcid">PMC2815961</pub-id></element-citation></ref><ref id="B140-vaccines-08-00621"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Skoff</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Halse</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Tondella</surname><given-names>M.L.</given-names></name><collab>CDC Pertussis Working Group</collab></person-group><article-title>Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.3201/eid2202.151332</pub-id><pub-id pub-id-type="pmid">26812174</pub-id><pub-id pub-id-type="pmcid">PMC4734536</pub-id></element-citation></ref><ref id="B141-vaccines-08-00621"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouchez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cantinelli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dore</surname><given-names>G.</given-names></name><name name-style="western"><surname>Njamkepo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guiso</surname><given-names>N.</given-names></name></person-group><article-title>First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>6034</fpage><lpage>6041</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.074</pub-id><pub-id pub-id-type="pmid">19666155</pub-id></element-citation></ref><ref id="B142-vaccines-08-00621"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barkoff</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Mertsola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pierard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoegh</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Guillot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stefanelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>van Gent</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berbers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vestrheim</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Pertactin-deficient Bordetella pertussis isolates: Evidence of increased circulation in Europe, 1998 to 2015</article-title><source>Euro Surveill.</source><year>2019</year><volume>24</volume><fpage>1700832</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2019.24.7.1700832</pub-id><pub-id pub-id-type="pmid">30782265</pub-id><pub-id pub-id-type="pmcid">PMC6381657</pub-id></element-citation></ref><ref id="B143-vaccines-08-00621"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyaji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Toyoizumi-Ajisaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shibayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kamachi</surname><given-names>K.</given-names></name></person-group><article-title>Genetic Analysis of Bordetella pertussis Isolates from the 2008&#8211;2010 Pertussis Epidemic in Japan</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e77165</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0077165</pub-id><pub-id pub-id-type="pmid">24124606</pub-id><pub-id pub-id-type="pmcid">PMC3790747</pub-id></element-citation></ref><ref id="B144-vaccines-08-00621"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorji</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yantorno</surname><given-names>O.</given-names></name><name name-style="western"><surname>Deora</surname><given-names>R.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mukkur</surname><given-names>T.K.</given-names></name></person-group><article-title>Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance</article-title><source>Med. Microbiol. Immunol.</source><year>2018</year><volume>207</volume><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s00430-017-0524-z</pub-id><pub-id pub-id-type="pmid">29164393</pub-id></element-citation></ref><ref id="B145-vaccines-08-00621"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decker</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>James</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Stibitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hinton</surname><given-names>D.M.</given-names></name></person-group><article-title>The Bordetella pertussis model of exquisite gene control by the global transcription factor BvgA</article-title><source>Microbiology</source><year>2012</year><volume>158</volume><fpage>1665</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1099/mic.0.058941-0</pub-id><pub-id pub-id-type="pmid">22628479</pub-id><pub-id pub-id-type="pmcid">PMC3542142</pub-id></element-citation></ref><ref id="B146-vaccines-08-00621"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karimova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bellalou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ullmann</surname><given-names>A.</given-names></name></person-group><article-title>Phosphorylation-dependent binding of BvgA to the upstream region of the cyaA gene of Bordetella pertussis</article-title><source>Mol. Microbiol.</source><year>1996</year><volume>20</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1996.5231057.x</pub-id><pub-id pub-id-type="pmid">8736528</pub-id></element-citation></ref><ref id="B147-vaccines-08-00621"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamanova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kofronova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Masin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Genth</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vojtova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Linhartova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Benada</surname><given-names>O.</given-names></name><name name-style="western"><surname>Just</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sebo</surname><given-names>P.</given-names></name></person-group><article-title>Adenylate Cyclase Toxin Subverts Phagocyte Function by RhoA Inhibition and Unproductive Ruffling</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>5587</fpage><lpage>5597</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5587</pub-id><pub-id pub-id-type="pmid">18832717</pub-id></element-citation></ref><ref id="B148-vaccines-08-00621"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arciniega</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hewlett</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Deforest</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wassilak</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Onorato</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Manclark</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>D.L.</given-names></name></person-group><article-title>Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis</article-title><source>J. Infect. Dis.</source><year>1991</year><volume>163</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1093/infdis/163.1.135</pub-id><pub-id pub-id-type="pmid">1984460</pub-id></element-citation></ref><ref id="B149-vaccines-08-00621"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farfel</surname><given-names>Z.</given-names></name><name name-style="western"><surname>K&#246;nen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiertz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klapmuts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Addy</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hanski</surname><given-names>E.</given-names></name></person-group><article-title>Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination</article-title><source>J. Med. Microbiol.</source><year>1990</year><volume>32</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1099/00222615-32-3-173</pub-id><pub-id pub-id-type="pmid">2374155</pub-id></element-citation></ref><ref id="B150-vaccines-08-00621"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arciniega</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hewlett</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>D.L.</given-names></name></person-group><article-title>Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>1993</year><volume>6</volume><fpage>325</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.1993.tb00345.x</pub-id><pub-id pub-id-type="pmid">8499896</pub-id></element-citation></ref><ref id="B151-vaccines-08-00621"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guiso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rocancourt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szatanik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>J.</given-names></name></person-group><article-title>Bordetella adenylate cyclase is a virulent associated factor and an immunoprotective antigen</article-title><source>Microb. Pathog.</source><year>1989</year><volume>7</volume><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/0882-4010(89)90040-5</pub-id><pub-id pub-id-type="pmid">2622329</pub-id></element-citation></ref><ref id="B152-vaccines-08-00621"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hormozi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Parton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coote</surname><given-names>J.</given-names></name></person-group><article-title>Adjuvant and protective properties of native and recombinant Bordetella pertussis adenylate cyclase toxin preparations in mice</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>1999</year><volume>23</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.1999.tb01248.x</pub-id><pub-id pub-id-type="pmid">10225286</pub-id></element-citation></ref><ref id="B153-vaccines-08-00621"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guiso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Szatanik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rocancourt</surname><given-names>M.</given-names></name></person-group><article-title>Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization</article-title><source>Microb. Pathog.</source><year>1991</year><volume>11</volume><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/0882-4010(91)90038-C</pub-id><pub-id pub-id-type="pmid">1795632</pub-id></element-citation></ref><ref id="B154-vaccines-08-00621"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khelef</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guiso</surname><given-names>N.</given-names></name></person-group><article-title>Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection</article-title><source>Microb. Pathog.</source><year>1992</year><volume>12</volume><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/0882-4010(92)90057-U</pub-id><pub-id pub-id-type="pmid">1614333</pub-id></element-citation></ref><ref id="B155-vaccines-08-00621"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>G.Y.C.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Prior</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Parton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coote</surname><given-names>J.G.</given-names></name></person-group><article-title>Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>6797</fpage><lpage>6805</lpage><pub-id pub-id-type="doi">10.1128/IAI.01104-06</pub-id><pub-id pub-id-type="pmid">16982827</pub-id><pub-id pub-id-type="pmcid">PMC1698075</pub-id></element-citation></ref><ref id="B156-vaccines-08-00621"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Donato</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hewlett</surname><given-names>E.L.</given-names></name></person-group><article-title>Newly secreted adenylate cyclase toxin is responsible for intoxication of target cells by Bordetella pertussis</article-title><source>Mol. Microbiol.</source><year>2004</year><volume>53</volume><fpage>1709</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2004.04227.x</pub-id><pub-id pub-id-type="pmid">15341649</pub-id></element-citation></ref><ref id="B157-vaccines-08-00621"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Farfel</surname><given-names>Z.</given-names></name></person-group><article-title>Bordetella pertussis invasive adenylate cyclase. Partial resolution and properties of its cellular penetration</article-title><source>J. Biol. Chem.</source><year>1985</year><volume>260</volume><fpage>5526</fpage><lpage>5532</lpage><pub-id pub-id-type="pmid">2859287</pub-id></element-citation></ref><ref id="B158-vaccines-08-00621"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Hewlett</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Maynard</surname><given-names>J.A.</given-names></name></person-group><article-title>The Bordetella adenylate cyclase repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies</article-title><source>J. Biol. Chem.</source><year>2015</year><volume>290</volume><fpage>3576</fpage><lpage>3591</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.585281</pub-id><pub-id pub-id-type="pmid">25505186</pub-id><pub-id pub-id-type="pmcid">PMC4319024</pub-id></element-citation></ref><ref id="B159-vaccines-08-00621"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boehm</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>DiVenere</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sen-Kilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bevere</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>DeRoos</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice</article-title><source>Infect. Immun.</source><year>2018</year><volume>86</volume><fpage>e00857-17</fpage><pub-id pub-id-type="doi">10.1128/IAI.00857-17</pub-id><pub-id pub-id-type="pmid">30012638</pub-id><pub-id pub-id-type="pmcid">PMC6204743</pub-id></element-citation></ref><ref id="B160-vaccines-08-00621"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>A.A.</given-names></name></person-group><article-title>BrkA Protein of Bordetella pertussis Inhibits the Classical Pathway of Complement after C1 Deposition</article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>3067</fpage><lpage>3072</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.5.3067-3072.2001</pub-id><pub-id pub-id-type="pmid">11292725</pub-id><pub-id pub-id-type="pmcid">PMC98261</pub-id></element-citation></ref><ref id="B161-vaccines-08-00621"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marr</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>V.</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Denoel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>R.C.</given-names></name></person-group><article-title>Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>4306</fpage><lpage>4311</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.06.017</pub-id><pub-id pub-id-type="pmid">18582518</pub-id></element-citation></ref><ref id="B162-vaccines-08-00621"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gasperini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Biagini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gianfaldoni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Norais</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bensi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delany</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aric&#242;</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing to Bordetella pertussis Adhesion to Epithelial Cells</article-title><source>Mol. Cell. Proteom.</source><year>2018</year><volume>17</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA117.000045</pub-id><pub-id pub-id-type="pmid">29203497</pub-id><pub-id pub-id-type="pmcid">PMC5795387</pub-id></element-citation></ref><ref id="B163-vaccines-08-00621"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Gouw</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Hermans</surname><given-names>P.W.M.</given-names></name><name name-style="western"><surname>Wessels</surname><given-names>H.J.C.T.</given-names></name><name name-style="western"><surname>Zomer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berends</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berbers</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Diavatopoulos</surname><given-names>D.A.</given-names></name></person-group><article-title>Proteomics-Identified Bvg-Activated Autotransporters Protect against Bordetella pertussis in a Mouse Model</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e105011</elocation-id><pub-id pub-id-type="pmid">25133400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0105011</pub-id><pub-id pub-id-type="pmcid">PMC4136822</pub-id></element-citation></ref><ref id="B164-vaccines-08-00621"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine Adjuvants: Putting Innate Immunity to Work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="B165-vaccines-08-00621"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baraff</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Beckwith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Strome</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marcy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Manclark</surname><given-names>C.R.</given-names></name></person-group><article-title>Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: Follow-up evaluation</article-title><source>Pediatrics</source><year>1988</year><volume>81</volume><fpage>789</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">3259305</pub-id></element-citation></ref><ref id="B166-vaccines-08-00621"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>MacLeod</surname><given-names>M.K.L.</given-names></name><name name-style="western"><surname>Kappler</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Marrack</surname><given-names>P.</given-names></name></person-group><article-title>Immune mechanisms of protection: Can adjuvants rise to the challenge?</article-title><source>BMC Biol.</source><year>2010</year><volume>8</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7007-8-37</pub-id><pub-id pub-id-type="pmid">20385031</pub-id><pub-id pub-id-type="pmcid">PMC2864095</pub-id></element-citation></ref><ref id="B167-vaccines-08-00621"><label>167.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ghezzi</surname><given-names>P.</given-names></name></person-group><article-title>Animal Models of Endotoxic Shock</article-title><source>Tumor Necrosis Factor</source><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2004</year><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/1-59259-771-8:199</pub-id><pub-id pub-id-type="pmid">15064441</pub-id></element-citation></ref><ref id="B168-vaccines-08-00621"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenny</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Waddington</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>U.</given-names></name></person-group><article-title>Immunological notes. XVII&#8211;XXIV</article-title><source>J. Pathol. Bacteriol.</source><year>1926</year><volume>29</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/path.1700290106</pub-id></element-citation></ref><ref id="B169-vaccines-08-00621"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>McCluskey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hams</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fallon</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name></person-group><article-title>The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses</article-title><source>Eur. J. Immunol.</source><year>2018</year><volume>48</volume><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1002/eji.201747150</pub-id><pub-id pub-id-type="pmid">29349774</pub-id></element-citation></ref><ref id="B170-vaccines-08-00621"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenny</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Buttle</surname><given-names>G.A.H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>M.F.</given-names></name></person-group><article-title>Rate of disappearance of diphtheria toxoid injected into rabbits and guinea - pigs: Toxoid precipitated with alum</article-title><source>J. Pathol. Bacteriol.</source><year>1931</year><volume>34</volume><fpage>267</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1002/path.1700340214</pub-id></element-citation></ref><ref id="B171-vaccines-08-00621"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>W.T.</given-names></name></person-group><article-title>Some Observations on the Use of Alum Precipitated Diphtheria Toxoid</article-title><source>Am. J. Public Health Nation&#8217;s Health</source><year>1935</year><volume>25</volume><fpage>298</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.2105/AJPH.25.3.298</pub-id><pub-id pub-id-type="pmid">18014174</pub-id><pub-id pub-id-type="pmcid">PMC1559051</pub-id></element-citation></ref><ref id="B172-vaccines-08-00621"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morefield</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Sokolovska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>HogenEsch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Hem</surname><given-names>S.L.</given-names></name></person-group><article-title>Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1588</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.07.050</pub-id><pub-id pub-id-type="pmid">15694511</pub-id></element-citation></ref><ref id="B173-vaccines-08-00621"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J.P.-Y.</given-names></name><name name-style="western"><surname>Re</surname><given-names>F.</given-names></name></person-group><article-title>Cutting Edge: Inflammasome Activation by Alum and Alum&#8217;s Adjuvant Effect Are Mediated by NLRP3</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.1.17</pub-id><pub-id pub-id-type="pmid">18566365</pub-id><pub-id pub-id-type="pmcid">PMC2587213</pub-id></element-citation></ref><ref id="B174-vaccines-08-00621"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nookala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Re</surname><given-names>F.</given-names></name></person-group><article-title>Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>5271</fpage><lpage>5276</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.8.5271</pub-id><pub-id pub-id-type="pmid">17404311</pub-id></element-citation></ref><ref id="B175-vaccines-08-00621"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>G.</given-names></name></person-group><article-title>The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity</article-title><source>Eur. J. Immunol.</source><year>2008</year><volume>38</volume><fpage>2085</fpage><lpage>2089</lpage><pub-id pub-id-type="doi">10.1002/eji.200838549</pub-id><pub-id pub-id-type="pmid">18624356</pub-id><pub-id pub-id-type="pmcid">PMC2759997</pub-id></element-citation></ref><ref id="B176-vaccines-08-00621"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ozasa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Tajber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corrigan</surname><given-names>O.I.</given-names></name><name name-style="western"><surname>McNeela</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses</article-title><source>Eur. J. Immunol.</source><year>2012</year><volume>42</volume><fpage>2709</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.1002/eji.201242372</pub-id><pub-id pub-id-type="pmid">22777876</pub-id></element-citation></ref><ref id="B177-vaccines-08-00621"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Correlates of protection induced by vaccination</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>1055</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1128/CVI.00131-10</pub-id><pub-id pub-id-type="pmid">20463105</pub-id><pub-id pub-id-type="pmcid">PMC2897268</pub-id></element-citation></ref><ref id="B178-vaccines-08-00621"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stenger</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Gremmer</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Dormans</surname><given-names>J.A.M.A.</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Kimman</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Vandebriel</surname><given-names>R.J.</given-names></name></person-group><article-title>The role of Toll-like receptor-4 in pertussis vaccine-induced immunity</article-title><source>BMC Immunol.</source><year>2008</year><volume>9</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2172-9-21</pub-id><pub-id pub-id-type="pmid">18498620</pub-id><pub-id pub-id-type="pmcid">PMC2409298</pub-id></element-citation></ref><ref id="B179-vaccines-08-00621"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Errea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Maele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sirard</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Benecke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hozbor</surname><given-names>D.</given-names></name></person-group><article-title>Toll-like receptor 4 orchestrates neutrophil recruitment into airways during the first hours of Bordetella pertussis infection</article-title><source>Microbes Infect.</source><year>2013</year><volume>15</volume><fpage>708</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2013.06.010</pub-id><pub-id pub-id-type="pmid">23811096</pub-id></element-citation></ref><ref id="B180-vaccines-08-00621"><label>180.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Opal</surname><given-names>S.M.</given-names></name></person-group><article-title>Endotoxins and Other Sepsis Triggers</article-title><source>Endotoxemia and Endotoxin Shock</source><publisher-name>KARGER</publisher-name><publisher-loc>Basel, Switzerland</publisher-loc><year>2010</year><volume>Volume 167</volume><fpage>14</fpage><lpage>24</lpage><isbn>0302-5144</isbn><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000315915</pub-id><pub-id pub-id-type="pmid">20519895</pub-id></element-citation></ref><ref id="B181-vaccines-08-00621"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ireton</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Adjuvants containing natural and synthetic Toll-like receptor 4 ligands</article-title><source>Expert Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>793</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.811204</pub-id><pub-id pub-id-type="pmid">23885824</pub-id></element-citation></ref><ref id="B182-vaccines-08-00621"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Descamps</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wettendorff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M.</given-names></name></person-group><article-title>Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach</article-title><source>BioDrugs</source><year>2011</year><volume>25</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.2165/11591760-000000000-00000</pub-id><pub-id pub-id-type="pmid">21815697</pub-id></element-citation></ref><ref id="B183-vaccines-08-00621"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vandepapeliere</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horsmans</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carletti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wettendorff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M.</given-names></name></person-group><article-title>Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.10.078</pub-id><pub-id pub-id-type="pmid">25444781</pub-id></element-citation></ref><ref id="B184-vaccines-08-00621"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geurtsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banus</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Gremmer</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>H.</given-names></name><name name-style="western"><surname>de la Fonteyne-Blankestijn</surname><given-names>L.J.J.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Dormans</surname><given-names>J.A.M.A.</given-names></name><name name-style="western"><surname>Tommassen</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Ley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>Lipopolysaccharide Analogs Improve Efficacy of Acellular Pertussis Vaccine and Reduce Type I Hypersensitivity in Mice</article-title><source>Clin. Vaccine Immunol.</source><year>2007</year><volume>14</volume><fpage>821</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1128/CVI.00074-07</pub-id><pub-id pub-id-type="pmid">17494641</pub-id><pub-id pub-id-type="pmcid">PMC1951065</pub-id></element-citation></ref><ref id="B185-vaccines-08-00621"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brummelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Helm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hamstra</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>van der Ley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boog</surname><given-names>C.J.P.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.G.H.</given-names></name><name name-style="western"><surname>van Els</surname><given-names>C.A.C.M.</given-names></name></person-group><article-title>Modulation of the CD4+ T cell response after acellular pertussis vaccination in the presence of TLR4 ligation</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>1483</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.01.063</pub-id><pub-id pub-id-type="pmid">25659267</pub-id></element-citation></ref><ref id="B186-vaccines-08-00621"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brummelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raeven</surname><given-names>R.H.M.</given-names></name><name name-style="western"><surname>Helm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pennings</surname><given-names>J.L.A.</given-names></name><name name-style="western"><surname>Metz</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Eden</surname><given-names>W.</given-names></name><name name-style="western"><surname>van Els</surname><given-names>C.A.C.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.G.H.</given-names></name></person-group><article-title>Transcriptome signature for dampened Th2 dominance in acellular pertussis vaccine-induced CD4+ T cell responses through TLR4 ligation</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>25064</fpage><pub-id pub-id-type="doi">10.1038/srep25064</pub-id><pub-id pub-id-type="pmid">27118638</pub-id><pub-id pub-id-type="pmcid">PMC4846868</pub-id></element-citation></ref><ref id="B187-vaccines-08-00621"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists</article-title><source>Adv. Drug Deliv. Rev.</source><year>2009</year><volume>61</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2008.12.008</pub-id><pub-id pub-id-type="pmid">19211030</pub-id></element-citation></ref><ref id="B188-vaccines-08-00621"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weeratna</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Brazolot Millan</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>McCluskie</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>H.L.</given-names></name></person-group><article-title>CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2001</year><volume>32</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2001.tb00535.x</pub-id><pub-id pub-id-type="pmid">11750224</pub-id></element-citation></ref><ref id="B189-vaccines-08-00621"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bode</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Steinhagen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kinjo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>CpG DNA as a vaccine adjuvant</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1586/erv.10.174</pub-id><pub-id pub-id-type="pmid">21506647</pub-id><pub-id pub-id-type="pmcid">PMC3108434</pub-id></element-citation></ref><ref id="B190-vaccines-08-00621"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asokanathan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name></person-group><article-title>A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.4161/hv.22755</pub-id><pub-id pub-id-type="pmcid">PMC3859755</pub-id><pub-id pub-id-type="pmid">23291942</pub-id></element-citation></ref><ref id="B191-vaccines-08-00621"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakazawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ichino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naruto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>S.</given-names></name></person-group><article-title>A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria&#8211;tetanus&#8211;pertussis vaccine</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>5450</fpage><lpage>5456</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.041</pub-id><pub-id pub-id-type="pmid">16006019</pub-id></element-citation></ref><ref id="B192-vaccines-08-00621"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakhshaei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Golara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdolmaleki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khosravi-Eghbal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khoshnoodi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Judaki</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Douraghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jeddi-Tehrani</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB/c Mice</article-title><source>J. Interf. Cytokine Res.</source><year>2018</year><volume>38</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1089/jir.2017.0060</pub-id><pub-id pub-id-type="pmid">29638208</pub-id></element-citation></ref><ref id="B193-vaccines-08-00621"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buonsanti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balocchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harfouche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corrente</surname><given-names>F.</given-names></name><name name-style="western"><surname>Galli Stampino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tontini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malyala</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bufali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>29063</fpage><pub-id pub-id-type="doi">10.1038/srep29063</pub-id><pub-id pub-id-type="pmid">27439378</pub-id><pub-id pub-id-type="pmcid">PMC4954951</pub-id></element-citation></ref><ref id="B194-vaccines-08-00621"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Torre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bacconi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sammicheli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arcidiacono</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galletti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laera</surname><given-names>D.</given-names></name><etal/></person-group><article-title>One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0147767</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0147767</pub-id><pub-id pub-id-type="pmid">26812180</pub-id><pub-id pub-id-type="pmcid">PMC4727907</pub-id></element-citation></ref><ref id="B195-vaccines-08-00621"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagnoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>R.P.N.</given-names></name><name name-style="western"><surname>Fiaschi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cartocci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nardi-Dei</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nosari</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Falco</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>3680</fpage><lpage>3685</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424924112</pub-id><pub-id pub-id-type="pmid">25775551</pub-id><pub-id pub-id-type="pmcid">PMC4378396</pub-id></element-citation></ref><ref id="B196-vaccines-08-00621"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.Y.-H.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Doro</surname><given-names>F.</given-names></name><name name-style="western"><surname>D&#8217;Oro</surname><given-names>U.</given-names></name><name name-style="western"><surname>Skibinski</surname><given-names>D.A.G.</given-names></name><name name-style="western"><surname>Mbow</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bufali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Rational design of small molecules as vaccine adjuvants</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>263ra160</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3009980</pub-id><pub-id pub-id-type="pmid">25411473</pub-id></element-citation></ref><ref id="B197-vaccines-08-00621"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leuzzi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Galletti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>D&#8217;Oro</surname><given-names>U.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>5256</fpage><lpage>5263</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.009</pub-id><pub-id pub-id-type="pmid">28823618</pub-id></element-citation></ref><ref id="B198-vaccines-08-00621"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine</article-title><source>Mucosal Immunol.</source><year>2015</year><volume>8</volume><fpage>607</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/mi.2014.93</pub-id><pub-id pub-id-type="pmid">25315966</pub-id></element-citation></ref><ref id="B199-vaccines-08-00621"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name></person-group><article-title>The cGAS-STING Pathway for DNA Sensing</article-title><source>Mol. Cell</source><year>2013</year><volume>51</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.07.004</pub-id><pub-id pub-id-type="pmid">23870141</pub-id><pub-id pub-id-type="pmcid">PMC3782533</pub-id></element-citation></ref><ref id="B200-vaccines-08-00621"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burdette</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>R.E.</given-names></name></person-group><article-title>STING and the innate immune response to nucleic acids in the cytosol</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/ni.2491</pub-id><pub-id pub-id-type="pmid">23238760</pub-id></element-citation></ref><ref id="B201-vaccines-08-00621"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burdette</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sotelo-Troha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwig</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>R.E.</given-names></name></person-group><article-title>STING is a direct innate immune sensor of cyclic di-GMP</article-title><source>Nature</source><year>2011</year><volume>478</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/nature10429</pub-id><pub-id pub-id-type="pmid">21947006</pub-id><pub-id pub-id-type="pmcid">PMC3203314</pub-id></element-citation></ref><ref id="B202-vaccines-08-00621"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature07317</pub-id><pub-id pub-id-type="pmid">18724357</pub-id><pub-id pub-id-type="pmcid">PMC2804933</pub-id></element-citation></ref><ref id="B203-vaccines-08-00621"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway</article-title><source>Sci. Signal.</source><year>2012</year><volume>5</volume><fpage>ra20</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2002521</pub-id><pub-id pub-id-type="pmid">22394562</pub-id><pub-id pub-id-type="pmcid">PMC3549669</pub-id></element-citation></ref><ref id="B204-vaccines-08-00621"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elahi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Kessel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kiros</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Strom</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>V.</given-names></name></person-group><article-title>c-di-GMP enhances protective innate immunity in a murine model of pertussis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e109778</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109778</pub-id><pub-id pub-id-type="pmid">25333720</pub-id><pub-id pub-id-type="pmcid">PMC4198122</pub-id></element-citation></ref><ref id="B205-vaccines-08-00621"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gschwandtner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Derler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Midwood</surname><given-names>K.S.</given-names></name></person-group><article-title>More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2759</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02759</pub-id><pub-id pub-id-type="pmid">31921102</pub-id><pub-id pub-id-type="pmcid">PMC6923224</pub-id></element-citation></ref><ref id="B206-vaccines-08-00621"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allavena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>J.</given-names></name><name name-style="western"><surname>J&#237;lek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sozzani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name></person-group><article-title>Induction of natural killer cell migration by monocyte chemotactic protein&#8722;1, &#8722;2 and &#8722;3</article-title><source>Eur. J. Immunol.</source><year>1994</year><volume>24</volume><fpage>3233</fpage><lpage>3236</lpage><pub-id pub-id-type="doi">10.1002/eji.1830241249</pub-id><pub-id pub-id-type="pmid">7805752</pub-id></element-citation></ref><ref id="B207-vaccines-08-00621"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreasen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carbonetti</surname><given-names>N.H.</given-names></name></person-group><article-title>Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>5139</fpage><lpage>5148</lpage><pub-id pub-id-type="doi">10.1128/IAI.00895-08</pub-id><pub-id pub-id-type="pmid">18765723</pub-id><pub-id pub-id-type="pmcid">PMC2573337</pub-id></element-citation></ref><ref id="B208-vaccines-08-00621"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temizoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ohata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jounai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ozasa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN</article-title><source>Eur. J. Immunol.</source><year>2015</year><volume>45</volume><fpage>1159</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1002/eji.201445132</pub-id><pub-id pub-id-type="pmid">25529558</pub-id><pub-id pub-id-type="pmcid">PMC4671267</pub-id></element-citation></ref><ref id="B209-vaccines-08-00621"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conway</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Madrigal-Estebas</surname><given-names>L.</given-names></name><name name-style="western"><surname>McClean</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brayden</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>1940</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00433-3</pub-id><pub-id pub-id-type="pmid">11228364</pub-id></element-citation></ref><ref id="B210-vaccines-08-00621"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindenstr&#248;m</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moguche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damborg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Urdahl</surname><given-names>K.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name></person-group><article-title>T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties</article-title><source>EBioMedicine</source><year>2018</year><volume>27</volume><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.12.004</pub-id><pub-id pub-id-type="pmid">29249639</pub-id><pub-id pub-id-type="pmcid">PMC5828549</pub-id></element-citation></ref><ref id="B211-vaccines-08-00621"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines in development</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2798-3</pub-id><pub-id pub-id-type="pmid">32967006</pub-id></element-citation></ref><ref id="B212-vaccines-08-00621"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shenton</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.C.</given-names></name></person-group><article-title>Novel approaches for the design, delivery and administration of vaccine technologies</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>196</volume><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/cei.13287</pub-id><pub-id pub-id-type="pmid">30963549</pub-id><pub-id pub-id-type="pmcid">PMC6468175</pub-id></element-citation></ref><ref id="B213-vaccines-08-00621"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>CD4 TRM Cells Following Infection and Immunization: Implications for More Effective Vaccine Design</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1860</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01860</pub-id><pub-id pub-id-type="pmid">30147701</pub-id><pub-id pub-id-type="pmcid">PMC6095996</pub-id></element-citation></ref><ref id="B214-vaccines-08-00621"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miquel-Clop&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Carding</surname><given-names>S.R.</given-names></name></person-group><article-title>Mucosal vaccines and technology</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>196</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1111/cei.13285</pub-id><pub-id pub-id-type="pmid">30963541</pub-id><pub-id pub-id-type="pmcid">PMC6468177</pub-id></element-citation></ref><ref id="B215-vaccines-08-00621"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perdomo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zedler</surname><given-names>U.</given-names></name><name name-style="western"><surname>K&#252;hl</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lozza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saikali</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Vogelzang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>S.H.E.</given-names></name><name name-style="western"><surname>Kupz</surname><given-names>A.</given-names></name></person-group><article-title>Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis</article-title><source>MBio</source><year>2016</year><volume>7</volume><fpage>e01686-16</fpage><pub-id pub-id-type="doi">10.1128/mBio.01686-16</pub-id><pub-id pub-id-type="pmid">27879332</pub-id><pub-id pub-id-type="pmcid">PMC5120139</pub-id></element-citation></ref><ref id="B216-vaccines-08-00621"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Stylianou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaveh</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pinpathomrat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pasricha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harrington-Kandt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garcia-Pelayo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Hogarth</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>McShane</surname><given-names>H.</given-names></name></person-group><article-title>Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1&#8722; CD4+ T cells</article-title><source>Mucosal Immunol.</source><year>2019</year><volume>12</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0109-1</pub-id><pub-id pub-id-type="pmid">30446726</pub-id><pub-id pub-id-type="pmcid">PMC7051908</pub-id></element-citation></ref><ref id="B217-vaccines-08-00621"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sogi</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Rae</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Surh</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Metchette</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Bruml</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection</article-title><source>Cell Rep.</source><year>2018</year><volume>23</volume><fpage>1435</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.003</pub-id><pub-id pub-id-type="pmid">29719256</pub-id><pub-id pub-id-type="pmcid">PMC6003617</pub-id></element-citation></ref><ref id="B218-vaccines-08-00621"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santosuosso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hitt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name></person-group><article-title>Mechanisms of mucosal and parenteral tuberculosis vaccinations: Adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen</article-title><source>J. Immunol.</source><year>2005</year><volume>174</volume><fpage>7986</fpage><lpage>7994</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.12.7986</pub-id><pub-id pub-id-type="pmid">15944305</pub-id></element-citation></ref><ref id="B219-vaccines-08-00621"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name></person-group><article-title>Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Gu&#233;rin Immunity</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>6353</fpage><lpage>6360</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.9.6353</pub-id><pub-id pub-id-type="pmid">17056566</pub-id></element-citation></ref><ref id="B220-vaccines-08-00621"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zganiacz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name></person-group><article-title>Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>238</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.1.238-246.2004</pub-id><pub-id pub-id-type="pmid">14688101</pub-id><pub-id pub-id-type="pmcid">PMC344011</pub-id></element-citation></ref><ref id="B221-vaccines-08-00621"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lopez-Roman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Perez-Herran</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gormley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rullas-Trincado</surname><given-names>J.</given-names></name><name name-style="western"><surname>Angulo-Barturen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name></person-group><article-title>Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>594</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1128/CVI.00700-13</pub-id><pub-id pub-id-type="pmid">24501340</pub-id><pub-id pub-id-type="pmcid">PMC3993116</pub-id></element-citation></ref><ref id="B222-vaccines-08-00621"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barclay</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Busey</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Dalgard</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Good</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Janicki</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kasik</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Ribi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Wolinsky</surname><given-names>E.</given-names></name></person-group><article-title>Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin</article-title><source>Am. Rev. Respir. Dis.</source><year>1973</year><volume>107</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">4632221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/arrd.1973.107.3.351</pub-id></element-citation></ref><ref id="B223-vaccines-08-00621"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storsaeter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hallander</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Olin</surname><given-names>P.</given-names></name></person-group><article-title>Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>1907</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00227-8</pub-id><pub-id pub-id-type="pmid">9796042</pub-id></element-citation></ref><ref id="B224-vaccines-08-00621"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Locht</surname><given-names>C.</given-names></name></person-group><article-title>The Role of Mucosal Immunity in Pertussis</article-title><source>Front. Immunol.</source><year>2019</year><volume>9</volume><fpage>3068</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.03068</pub-id><pub-id pub-id-type="pmid">30692990</pub-id><pub-id pub-id-type="pmcid">PMC6339907</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-08-00621-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mechanisms of action of current and future pertussis vaccines. (<bold>a</bold>) Following immunization with current injectable aP vaccines formulated with alum, DCs at the site of injection take up antigens and migrate to draining lymph nodes where they activate differentiation of Th2 cells from naive T cells. Memory Th2 cells circulate, but do not home to respiratory tissues. IgG4 (IgG1 in mice) is produced by antigen-specific B cells, which protects against toxin-mediated pertussis disease but does not protect against nasal colonization with <italic toggle="yes">B. pertussis</italic>. (<bold>b</bold>) Following intranasal immunization with aP vaccines and novel adjuvants, pertussis OMV vaccines or live attenuated pertussis vaccines, local DCs are activated in the respiratory tract. These DCs migrate to draining lymph nodes and activate differentiation of na&#239;ve T cells into Th1 and Th17 cells, which have homing properties that facilitate migration to respiratory tissues. Th1 and Th17-type respiratory T<sub>RM</sub> cells produce IFN-&#947; and IL-17, which promote recruitment of macrophages and neutrophil to the lungs and nasal mucosae. Intranasal immunization with these vaccines also leads to B cell activation and the production of IgG1 (IgG2a/c in mice) antibodies as well as sIgA. Images from Servier Medical Art (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.smart.servier.com">www.smart.servier.com</uri>). Tn: na&#239;ve T cell, Bn: na&#239;ve B cell, T<sub>RM</sub>: tissue-resident memory T cell, DC: Dendritic cell, sIgA: secretory immunoglobulin-A, M&#934;: macrophage.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-08-00621-g001.jpg"/></fig><fig id="vaccines-08-00621-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mechanisms of action of novel adjuvants under investigation in experimental aP vaccines. Activation of signaling pathways in APC by various adjuvants can be harnessed to generate Th1/Th17 polarizing conditions following immunization. These include the TLR2 agonist LP1569 and the TLR4 agonists MPL, LpxL1 and LpxL2 which are synthetic analogues of LPS. SMIP7.10 and CpG ligate the endosomal TLRs, TLR7 and TLR 9 respectively. TLR 2, 4, 7 and 9 signal through the adaptor molecule MyD88, with TLR2 and TLR4 requiring the bridging adaptor Mal to activate MyD88-mediated signaling. MyD88 signaling results in downstream activation of NF&#954;B and MAPKs. MAPKs activate transcription factors such as AP-1. NF&#954;B and AP-1 translocate to the nucleus leading to the transcription of pro-inflammatory and T cell-polarizing cytokines, chemokines, MHC class II and costimulatory molecules. The CLR, Mincle, is ligated by the TDB component (shown in red) of liposomes, which signals via SYK, and subsequently activates CARD9-Bcl10-Malt signalosome and NF&#954;B. c-di-GMP activates the intracellular DNA sensor, STING, located at the ER, and complexed with TBK1 translocates to perinuclear regions, activating NF&#954;B and IRF3. LP-GMP, which combines LP1569 and c-di-GMP adjuvants, signals through TLR2 and STING respectively, resulting in synergistic induction of Th1/Th17 responses. Block arrows denote activation and dashed arrows denote translocation of transcription factors to the nucleus. Images from Servier Medical Art (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.smart.servier.com">www.smart.servier.com</uri>). APC: antigen presenting cell, TLR: Toll-like receptor, Th: T helper cell, MPL: Monophosphoryl lipid A, LPS: Lipopolysaccharide, MyD88: Myeloid differentiation primary response gene 88, Mal: MyD88 adaptor-like, NF-&#954;B: Nuclear Factor kappa B, MAPK: Mitogen-activated tyrosine kinase, TDB: &#945;,&#945; trehalose 6,6&#8217;-dibehenate, SYK: Spleen tyrosine kinase, CARD9: Caspase recruitment domain family member 9, Bcl10: B-cell lymphoma 10, Malt1: Mucosa-associated lymphoid tissue 1, AP1: Activator protein 1, IRF3: Interferon response factor 3, STING: Stimulator of interferon genes, TBK1: TANK-binding kinase 1, MHC Class II: Major histocompatibility complex class II, Costim: costimulatory molecules.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-08-00621-g002.jpg"/></fig></floats-group></article></pmc-articleset>